Medicare Benefits Schedule Review Taskforce Report from ...
Medicare Benefits Schedule Review TaskforceReport from the Pathology Clinical Committee – ImmunologyFebruary 2018Important noteThe views and recommendations in this report from the Clinical Committee have been released for the purpose of seeking the views of stakeholders. This report does not constitute the final position on these items, which is subject to: Stakeholder feedback.ThenConsideration by the MBS Review Taskforce.Then, if endorsed, consideration byThe Minister for Health. The Government.Stakeholders should provide comment on the recommendations via mbsreviews@.au.Confidentiality of comments: If you would like your feedback to remain confidential, please mark it as such. It is important to be aware that confidential feedback may still be subject to access under freedom of information law.Table of Contents TOC \o "1-2" \t "Rec,2" 1.Executive summary PAGEREF _Toc499293020 \h 51.1The Pathology Clinical Committee PAGEREF _Toc499293022 \h 51.2Recommendations PAGEREF _Toc499293023 \h 51.3Consumer engagement PAGEREF _Toc499293024 \h 62.About the Medicare Benefits Schedule (MBS) Review PAGEREF _Toc499293025 \h 82.1Medicare and the MBS PAGEREF _Toc499293026 \h 82.2The MBS Review Taskforce PAGEREF _Toc499293027 \h 82.3The Taskforce’s approach PAGEREF _Toc499293028 \h 93.About the Pathology Clinical Committee PAGEREF _Toc499293029 \h 113.1Committee members PAGEREF _Toc499293030 \h 113.2Immunology Working Group PAGEREF _Toc499293031 \h 123.3Conflicts of interest PAGEREF _Toc499293032 \h 123.4Areas of responsibility of the Committee PAGEREF _Toc499293033 \h 123.5Summary of the Committee’s review approach PAGEREF _Toc499293034 \h 124.Recommendations for immunology-related pathology tests PAGEREF _Toc499293035 \h 144.2Coeliac disease panel: items 71163, 71164 PAGEREF _Toc499293036 \h 144.3Genotyping for coeliac disease risk for DQ2 and DQ8: item 71151 PAGEREF _Toc499293037 \h 164.4Specific immunoglobulin E antibodies: item 71079 PAGEREF _Toc499293038 \h 174.5Antinuclear antibodies tests: item 71097 PAGEREF _Toc499293039 \h 194.6Double-stranded DNA antibodies: item 71099 PAGEREF _Toc499293040 \h 204.7Antibodies to extractable nuclear antigens: items 71101 and 71103 PAGEREF _Toc499293041 \h 214.8Quantitation of complement components: items 71083, 71085, 71087, 71089, 71091 and 71093 PAGEREF _Toc499293042 \h 224.9Antibodies to tissue antigens: items 71119, 71121, 71123 and 71125 PAGEREF _Toc499293043 \h 234.10Antibodies to tissue antigens: item 71165 PAGEREF _Toc499293044 \h 244.11Quantitation of immunoglobulin E: items 71075 and 71077 PAGEREF _Toc499293045 \h 254.12Quantitation of total immunoglobulin A: item 71066 PAGEREF _Toc499293046 \h 264.13Quantitation of total immunoglobulin M: item 71072 PAGEREF _Toc499293047 \h 274.14Quantitation of total immunoglobulin D: item 71074 PAGEREF _Toc499293048 \h 284.15Cryoglobulins or cryofibrinogen: item 71064 PAGEREF _Toc499293049 \h 284.16Rheumatoid factor: item 71106 PAGEREF _Toc499293050 \h 294.17Antibody to cardiolipin: items 71180, 71183, 71186 PAGEREF _Toc499293051 \h 304.18Free kappa and lambda light chains: item 71200 PAGEREF _Toc499293052 \h 314.19Items to be deleted PAGEREF _Toc499293053 \h 324.20No changes PAGEREF _Toc499293054 \h 325.Referred items PAGEREF _Toc499293055 \h 355.1Erythrocyte sedimentation rate (ESR) PAGEREF _Toc499293056 \h 356.Recommendations to the Medical Services Advisory Committee PAGEREF _Toc499293057 \h 366.1Neuromyelitis optica (NMO) antibody testing PAGEREF _Toc499293058 \h 366.2Antibodies to citrullinated peptide antigens PAGEREF _Toc499293059 \h 367.References PAGEREF _Toc499293060 \h 388.Glossary PAGEREF _Toc499293061 \h 39Appendix A – Immunology-related pathology test items – recommendations list PAGEREF _Toc499293062 \h 40Appendix B – Summary for consumers PAGEREF _Toc499293063 \h 45List of tables and figures TOC \h \z \t "Caption" \c Figure 1. Prioritisation matrix PAGEREF _Toc499289237 \h 10Table 1. Pathology Clinical Committee members PAGEREF _Toc499289238 \h 11Table 2. Immunology Working Group members PAGEREF _Toc499289239 \h 12Table 3. Item introduction table for items 71163, 71164 PAGEREF _Toc499289240 \h 14Table 4. Current and proposed item descriptors for items 71163 and 71164 PAGEREF _Toc499289241 \h 15Table 5. Item introduction table for item 71151 PAGEREF _Toc499289242 \h 16Table 6. Current and proposed item descriptors for item 71151 and new item PAGEREF _Toc499289243 \h 16Table 7. Item introduction table for item 71079 PAGEREF _Toc499289244 \h 17Table 8. Current and proposed item descriptors for item 71079 and new item PAGEREF _Toc499289245 \h 18Table 9. Item introduction table for item 71097 PAGEREF _Toc499289246 \h 19Table 10. Current and proposed item descriptors for item 71097 PAGEREF _Toc499289247 \h 19Table 11. Item introduction table for item 71099 PAGEREF _Toc499289248 \h 20Table 12. Current and proposed item descriptors for item 71099 PAGEREF _Toc499289249 \h 20Table 13. Item introduction table for items 71101 and 71103 PAGEREF _Toc499289250 \h 21Table 14. Item introduction table for items 71083, 71085, 71087, 71089, 71091 and 71093 PAGEREF _Toc499289251 \h 22Table 15. Current and proposed item descriptors for items 71083, 71085, 71087, 71089, 71091 and 71093 PAGEREF _Toc499289252 \h 22Table 16. Item introduction table for items 71119, 71121, 71123 and 71125 PAGEREF _Toc499289253 \h 23Table 17. Current and proposed item descriptors for items 71119, 71121, 71123, 71125 PAGEREF _Toc499289254 \h 24Table 18. Item introduction table for item 71165 PAGEREF _Toc499289255 \h 24Table 19. Current and proposed item descriptors for item 71165 PAGEREF _Toc499289256 \h 25Table 20. Item introduction table for item 71075 and 71077 PAGEREF _Toc499289257 \h 25Table 21. Current and proposed item descriptors for items 71075 and 71077 PAGEREF _Toc499289258 \h 26Table 22. Item introduction table for item 71066 PAGEREF _Toc499289259 \h 26Table 23. Current and proposed item descriptors for item 71066 PAGEREF _Toc499289260 \h 27Table 24. Item introduction table for item 71072 PAGEREF _Toc499289261 \h 27Table 26. Current and proposed item descriptors for item 71072 PAGEREF _Toc499289262 \h 27Table 27. Item introduction table for item 71074 PAGEREF _Toc499289263 \h 28Table 28. Current and proposed item descriptors for item 71074 PAGEREF _Toc499289264 \h 28Table 28. Item introduction table for item 71064 PAGEREF _Toc499289265 \h 28Table 29. Item introduction table for item 71106 PAGEREF _Toc499289266 \h 29Table 30. Item introduction table for items 71180, 71183, 71186 PAGEREF _Toc499289267 \h 30Table 31. Current and proposed item descriptors for item 71180 PAGEREF _Toc499289268 \h 31Table 32. Item introduction table for item 71200 PAGEREF _Toc499289269 \h 31Table 33. Current and proposed item descriptors for item 71200 PAGEREF _Toc499289270 \h 31Table 34. Items to be deleted PAGEREF _Toc499289271 \h 32Table 35. MBS items that do not require amendment PAGEREF _Toc499289272 \h 32Table 36. Item introduction for item 65060 PAGEREF _Toc499289273 \h 35Table 37. Proposed new item descriptor for antibodies to citrullinated peptide antigens PAGEREF _Toc499289274 \h 36Table A1. MBS items considered by the committee PAGEREF _Toc499289275 \h 40Executive summaryThe Medicare Benefits Schedule (MBS) Review Taskforce (the Taskforce) is undertaking a program of work that considers how more than 5,700 items on the MBS can be aligned with contemporary clinical evidence and practice and improve health outcomes for patients. The Taskforce also seeks to identify any services that may be unnecessary, outdated or potentially unsafe.The Taskforce is committed to providing recommendations to the Minister for Health (the Minister) that will allow the MBS to deliver on each of these four key goals:Affordable and universal accessBest practice health servicesValue for the individual patientValue for the health system.The Taskforce has endorsed a methodology whereby the necessary clinical review of MBS items is undertaken by clinical committees and working groups. The Taskforce has asked the clinical committees to undertake the following tasks: Consider whether there are MBS items that are obsolete and should be removed from the MBS. Consider identified priority reviews of selected MBS services. Develop a program of work to consider the balance of MBS services within its remit and items assigned to the committee. Advise the Taskforce on relevant general MBS issues identified by the committee in the course of its deliberations. The recommendations from the clinical committees are released for stakeholder consultation. The clinical committees will consider feedback from stakeholders then provide recommendations to the Taskforce in review reports. The Taskforce will consider the review reports from clinical committees and stakeholder feedback before making recommendations to the Minister for consideration by Government. The Pathology Clinical CommitteeThe Pathology Clinical Committee (the Committee) was established in 2016 to make recommendations to the Taskforce on the review of MBS items within its remit, based on rapid evidence review and clinical expertise.Most recommendations relating to these items are included in this report for consultation. The Committee also provided recommendations on items that will be referred to other committees for consultation. An inclusive set of stakeholders is now engaged in consultation on the recommendations outlined in this report. Following this stakeholder consultation, the recommendations will be finalised and presented to the Taskforce. The Taskforce will consider the report and stakeholder feedback before making recommendations to the Minister for Health for consideration by the Government. RecommendationsThe Committee was assigned 72 MBS immunology items to review. The Committee’s recommendations for stakeholder consultation are that:four items be deleted from the MBSfive items be added21 items should be changed40 items should remain unchanged. These changes focus on encouraging best practice, modernising the MBS to reflect contemporary practice, and ensuring that MBS services provide value for the patient and the healthcare system.Major changes to items are summarised below and detailed descriptions of all recommendations are found in the body of this report. A plain English summary of all changes can be found in REF _Ref499282992 \h Appendix B – Summary for consumers.Antinuclear antibodiesThe Committee recommends limiting the use of item 71097, changing the wording of the descriptor, and educating requesters about optimal use of the item.The Committee has noted that repeat testing under Medicare is problematic for this item for two main reasons: tests are requested too many times; and lack of understanding by requesters of the intended use of this item. The recommendation for the education program aligns with a separate proposal for antinuclear antibody training to be a requirement for rheumatologists and the as-yet unpublished guidelines on use of antinuclear antibodies.Quantitation of complement componentsThe Committee recommends changes to the descriptors and tests included in each of the items in this group. The knowledge and utility of more complex testing has advanced in medicine, with many new applications being relevant to the investigation of disease.The Committee recommends removing properdin and factor B from items 71083–71087, as this test is of limited clinical use. The Committee also recommends deleting item 71087 (testing for three of the preceding items), as this is no longer applicable because the grouping will subsequently only contain two items, that is, testing for C3 and/or C4. The Committee recommends removing the wording specifying breakdown products of complement proteins and replacing the wording with other than C3 or C4 from items 71089–71093. Erythrocyte sedimentation rate (ESR) guidelinesWhile the Committee considers ESR to have a limited clinical role and that the evidence supporting the various clinical uses of ESR testing are poor, the recommendation is to retain this test on the MBS. This is in part due to the retention of ESR in some prognosis scoring systems and Pharmaceutical Benefits Scheme authority criteria.Consumer engagement and impactThe Committee includes experienced and committed health practitioners and consumer representatives. This section summarises the report’s key recommendations from a consumer perspective. It aims to make it easier for health consumers and members of the general public to understand the report’s recommendations. A complete list of the recommendations can be found in Appendix B, including a description in plain English of the medical service and the Committee’s recommendation, as well as an explanation of why the recommendation has been made. Consumers rarely engage with MBS item numbers unless they are following up on out-of-pocket expenses. Nevertheless, item descriptions and restrictions are an important part of healthcare accountability. The Committee’s recommendations encourage agreed best practice and reflect current clinical evidence. Both consumers and clinicians are expected to benefit from these recommendations because they address concerns regarding consumer safety and quality of care, and take steps to simplify the MBS and make it easier to use and understand. Consumer access to services was considered for each recommendation. The Committee also considered the impact of each recommendation on requestor and provider groups to ensure that changes were reasonable and fair. However, if the Committee identified evidence of potential item misuse or safety concerns, recommendations were made to encourage best practice, in line with the overarching purpose of the MBS Review. The Committee expects these recommendations to support better requesting, with the aim of ensuring that patients are provided with clinically indicated, high-quality care that reflects modern best practice. The consumer representatives used the following framework to assess recommendations:Safety: None of the recommendations negatively affects the safety of pathology services.Quality: Many of the recommended changes are intended to improve quality, primarily by aligning the reimbursement system with evidence-based practice. Access: The recommendations do not negatively affect appropriate access. However, some patient groups have been receiving services they do not need, which can result in either negative health impacts or unnecessary cost. Inappropriate access was restricted where possible.Effectiveness: None of the recommendations reduces the effectiveness of pathology services. Cost-effectiveness: The recommendations will have a positive effect on cost-effectiveness because they make it easier to determine which patient groups should have access to specific tests and treatments. Accountability: Many of the changes include wording that facilitates future auditing for quality purposes.Data collection: Data collection for research, monitoring and auditing presents a huge opportunity for a revised MBS, and the recommendations should improve the opportunities to use this data for targeted research in the future.About the Medicare Benefits Schedule (MBS) ReviewMedicare and the MBSWhat is Medicare?Medicare is Australia’s universal health scheme that enables all Australian residents (and some overseas visitors) to have access to a wide range of health services and medicines at little or no cost. Introduced in 1984, Medicare has three components:free public hospital services for public patientssubsidised drugs covered by the Pharmaceutical Benefits Scheme (PBS)subsidised health professional services listed on the MBS.What is the MBS?The MBS is a listing of the health professional services subsidised by the Australian Government. There are more than 5,700 MBS items that provide benefits to patients for a comprehensive range of services, including consultations, diagnostic tests and operations. The MBS Review TaskforceWhat is the MBS Review Taskforce?The Government established the MBS Review Taskforce to review all 5,700 MBS items to ensure they are aligned with contemporary clinical evidence and practice and improve health outcomes for patients. The Taskforce will also modernise the MBS by identifying any services that may be unnecessary, outdated or potentially unsafe.What are the goals of the Taskforce?The Taskforce is committed to providing recommendations to the Minister that will allow the MBS to deliver on each of these four key goals:Affordable and universal access—the evidence demonstrates that the MBS supports very good access to primary care services for most Australians, particularly in urban Australia. However, despite increases in the specialist workforce over the last decade, access to many specialist services remains problematic, with some rural patients being particularly under-serviced.Best practice health services—one of the core objectives of the Review is to modernise the MBS, ensuring that individual items and their descriptors are consistent with contemporary best practice and the evidence base when possible. Although the Medical Services Advisory Committee (MSAC) plays a crucial role in thoroughly evaluating new services, the vast majority of existing MBS items predate this process and have never been reviewed.Value for the individual patient—another core objective of the Review is to have an MBS that supports the delivery of services that are appropriate to the patient’s needs, provide real clinical value and do not expose the patient to unnecessary risk or expense.Value for the health system—achieving the above elements of the vision will go a long way to achieving improved value for the health system overall. Reducing the volume of services that provide little or no clinical benefit will enable resources to be redirected to new and existing services that have proven benefit and are underused, particularly for patients who cannot readily access those services currently.The Taskforce’s approachThe Taskforce is reviewing the existing MBS items, with a primary focus on ensuring that individual items and usage meet the definition of best practice. Within the Taskforce’s brief there is considerable scope to review and advise on all aspects that would contribute to a modern, transparent and responsive system. This includes not only making recommendations about new items or services being added to the MBS, but also about a MBS structure that could better accommodate changing health service models.The Taskforce has made a conscious decision to be ambitious in its approach and seize this unique opportunity to recommend changes to modernise the MBS on all levels, from the clinical detail of individual items, through administrative rules and mechanisms, to structural, whole-of-MBS issues. The Taskforce will also develop a mechanism for the ongoing review of the MBS after the current Review is concluded.As the MBS Review is to be clinician-led, the Taskforce decided that clinical committees should conduct the detailed review of MBS items. The committees are broad-based in their membership, and members have been appointed in an individual capacity rather than as representatives of any organisation. The Taskforce asked all committees to review MBS items using a framework based on Appropriate Use Criteria accepted by the Taskforce (Elshaug). ADDIN EN.CITE <EndNote><Cite><Author>Elshaug</Author><Year>2012</Year><RecNum>54</RecNum><DisplayText> [1]</DisplayText><record><rec-number>54</rec-number><foreign-keys><key app="EN" db-id="05trxwd9pxaf9oeezd6xrte0pftav5ade0ww" timestamp="1507605256">54</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Elshaug, A. G.</author><author>Watt, A. M.</author><author>Mundy, L.</author><author>Willis, C. D.</author></authors></contributors><auth-address>Department of Health Care Policy, Harvard Medical School, Boston, MA, USA. elshaug@hcp.med.harvard.edu</auth-address><titles><title>Over 150 potentially low-value health care practices: an Australian study</title><secondary-title>Med J Aust</secondary-title><alt-title>The Medical journal of Australia</alt-title></titles><periodical><full-title>Med J Aust</full-title></periodical><pages>556-60</pages><volume>197</volume><number>10</number><edition>2012/11/21</edition><keywords><keyword>Australia</keyword><keyword>Health Services/*standards</keyword><keyword>Humans</keyword><keyword>Insurance Benefits</keyword><keyword>National Health Programs</keyword><keyword>Patient Safety</keyword><keyword>*Quality of Health Care</keyword><keyword>*Unnecessary Procedures</keyword></keywords><dates><year>2012</year><pub-dates><date>Nov 19</date></pub-dates></dates><isbn>1326-5377 (Electronic)
0025-729X (Linking)</isbn><accession-num>23163685</accession-num><work-type>Research Support, Non-U.S. Gov't</work-type><urls><related-urls><url>; [1]The framework consists of seven steps:Develop an initial fact base for all items under consideration, drawing on the relevant data and literature. Identify items that are obsolete, are of questionable clinical value, are misused and/or pose a risk to patient safety. This step includes prioritising items as ‘priority 1,’ ‘priority 2’ or ‘priority 3,’ using a prioritisation methodology (described in more detail below).Identify any issues, develop hypotheses for recommendations and create a work plan (including establishing working groups, when required) to arrive at recommendations for each item.Gather further data, clinical guidelines and relevant literature to make provisional recommendations and draft accompanying rationales, as per the work plan. This process begins with priority 1 items, continues with priority 2 items and concludes with priority 3 items. This step also involves consultation with relevant stakeholders within the committee, working groups, and relevant colleagues or colleges. For complex cases, full appropriate use criteria were developed for the item’s explanatory notes.Review the provisional recommendations and the accompanying rationales, and gather further evidence as required.Finalise the recommendations in preparation for broader stakeholder consultation.Incorporate feedback gathered during stakeholder consultation and finalise the Review Report, which provides recommendations for the Taskforce.All MBS items will be reviewed during the course of the MBS Review. However, given the breadth of, and timeframe for, the Review, each clinical committee had to develop a work plan and assign priorities, keeping in mind the objectives of the Review. Committees used a robust prioritisation methodology to focus their attention and resources on the most important items requiring review. This was determined based on a combination of two standard metrics, derived from the appropriate use criteria (Elshaug): ADDIN EN.CITE <EndNote><Cite><Author>Elshaug</Author><Year>2012</Year><RecNum>54</RecNum><DisplayText> [1]</DisplayText><record><rec-number>54</rec-number><foreign-keys><key app="EN" db-id="05trxwd9pxaf9oeezd6xrte0pftav5ade0ww" timestamp="1507605256">54</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>Elshaug, A. G.</author><author>Watt, A. M.</author><author>Mundy, L.</author><author>Willis, C. D.</author></authors></contributors><auth-address>Department of Health Care Policy, Harvard Medical School, Boston, MA, USA. elshaug@hcp.med.harvard.edu</auth-address><titles><title>Over 150 potentially low-value health care practices: an Australian study</title><secondary-title>Med J Aust</secondary-title><alt-title>The Medical journal of Australia</alt-title></titles><periodical><full-title>Med J Aust</full-title></periodical><pages>556-60</pages><volume>197</volume><number>10</number><edition>2012/11/21</edition><keywords><keyword>Australia</keyword><keyword>Health Services/*standards</keyword><keyword>Humans</keyword><keyword>Insurance Benefits</keyword><keyword>National Health Programs</keyword><keyword>Patient Safety</keyword><keyword>*Quality of Health Care</keyword><keyword>*Unnecessary Procedures</keyword></keywords><dates><year>2012</year><pub-dates><date>Nov 19</date></pub-dates></dates><isbn>1326-5377 (Electronic)
0025-729X (Linking)</isbn><accession-num>23163685</accession-num><work-type>Research Support, Non-U.S. Gov't</work-type><urls><related-urls><url>; [1]Service volume.The likelihood that the item needed to be revised, determined by indicators such as identified safety concerns, geographic or temporal variation, delivery irregularity, the potential misuse of indications or other concerns raised by the Committee (such as inappropriate co-claiming).For each item, these two metrics were ranked high, medium or low. These rankings were then combined to generate a priority ranking ranging from 1 to 3 (where priority 1 items are the highest priority and priority 3 items are the lowest priority for review), using a prioritisation matrix (Figure?1). The Committee used this priority ranking to organise its review of item numbers and apportion the amount of time spent on each item. Figure 1. Prioritisation matrixAbout the Pathology Clinical CommitteeThe Pathology Clinical Committee (the Committee) is part of the first tranche of clinical committees. It was established in 2016 to make recommendations to the Taskforce on the review of MBS items within its remit, based on rapid evidence review and clinical expertise. The Taskforce has asked the Committee to review pathology services as a priority mittee membersThe Committee consists of 18 members, whose names, positions/organisations and declared conflicts of interest are listed in REF _Ref499282755 \h Table 1. All members of the Taskforce, clinical committees and working groups were asked to declare any conflicts of interest at the start of their involvement and are reminded to update their declarations periodically.Table SEQ Table \* ARABIC 1. Pathology Clinical Committee membersNamePosition/organisationDeclared conflict of?interestAssociate Professor Peter StewartRoyal Prince Alfred Hospital (Public)NoneProfessor Rita Horvath South Eastern Area Laboratory Services (Public)NoneDr Debra Norris QML Pathology (Primary)NoneDr Michael Harrison Sullivan Nicolaides Pathology (Sonic)NoneAssociate Professor Ken?Sikaris Melbourne Pathology (Sonic)NoneDr Melody Caramins Specialist Diagnostic Services (Primary)NoneDr John Rowell Royal Brisbane & Women's HospitalNoneProfessor Dominic?MallonPathWestNoneDr Peter RobertsRyde Hospital (AESM)NoneAssociate Professor Anthony LandgrenAustralian Clinical LabsNoneAssociate Professor Mary-Jo Waters St Vincent's Pathology (CHA)NoneProfessor Richard?MaclsaacSt Vincent's HospitalNoneDr Emil DjakicGeneral practitionerNoneDr Bev RowbothamMBS Review TaskforceNoneDr Jill ThistlethwaiteGeneral practitionerNoneDr Gary LumDepartment of Health Medical AdvisorNoneMs Valerie HanrahanConsumers Health ForumNoneDr Robyn LindnerNational Prescribing ServiceNoneImmunology Working GroupThe IWG is one of six clinical working groups that have been established to support the work of the Committee. It was established to review immunology pathology items, and make recommendations to the Committee based on rapid evidence review and clinical expertise. The IWG consists of six members, whose names, positions/organisations and declared conflicts of interest are listed in REF _Ref499283228 \h Table 2 below.Table SEQ Table \* ARABIC 2. Immunology Working Group membersNamePosition/organisationDeclared conflict of?interestDr Daman LangguthSullivan Nicolaides PathologyNoneDr Theo de MalmancheNSW Health PathologyNoneDr Pravin HissariaSA Pathology/Royal AdelaideNoneDr Lucinda WallmanLaverty PathologyNoneDr Aniello IannuzziGeneral PractitionerNoneMr Adam FriederichConsumer representativeNoneConflicts of interestAll members of the Taskforce, clinical committees and working groups are asked to declare any conflicts of interest at the start of their involvement and reminded to update their declarations periodically.It is noted that most Committee members share a common conflict of interest in reviewing items that are a source of revenue for them (i.e. Committee members provide the services under review). This conflict is inherent in a clinician-led process, and having been acknowledged by the Committee and the Taskforce, it was agreed that this should not prevent a clinician from participating in the review.Areas of responsibility of the CommitteeThe Committee was assigned 69 MBS immunology items to review. In the financial year 2014–15 these items accounted for 3,904,839 services (out of a total of 128,786,630 pathology services) and $137,281,885 in benefits (out of a total of $2,652,998,768).A complete list of these items can be found in Appendix A of this report.Summary of the Committee’s review approachThe Committee completed a review of the 75 items across six meetings, during which it developed the recommendations and rationales outlined in Section 4. The Review drew on various types of MBS data, including data on: utilisation of items (services, benefits, patients, providers and growth rates)service provision (type of provider, geography of service provision)patients (demographics and services per patient)co-claiming or episodes of services (same-day claiming and claiming with specific items over time)additional provider and patient-level data, when required.The review also drew on data presented in the relevant literature and clinical guidelines, all of which are referenced in the report. The Committee will consider stakeholder feedback before finalising the recommendations and presenting them to the Taskforce. The Taskforce will consider the report and stakeholder feedback before making recommendations to the Minister for Health for consideration by the Government.Recommendations for immunology-related pathology testsThe Committee reviewed 69 assigned immunology items and made recommendations based on evidence and clinical expertise. The item-level recommendations are described below. A summary list of recommendations can be found in Appendix A and in the summary for consumers in Appendix B.The Committee’s recommendations for stakeholder consultation are that:six items be deleted from the MBSfive new items be added21 items should be changed37 items should remain unchanged.The changes focus on encouraging best practice, modernising the MBS to reflect contemporary practice, and ensuring that MBS services provide value for the patient and the healthcare system. Some of this can be achieved by:deleting items that are obsoleteconsolidating or splitting items to reflect contemporary practicemodernising item descriptors to reflect best practiceproviding clinical guidance for appropriate use through explanatory notes.Coeliac disease panel: items 71163, 71164Table SEQ Table \* ARABIC 3. Item introduction table for items 71163, 71164ItemLong item descriptorSchedule feeServices FY2014–15Benefits FY2014–15 Patient countServices 5-year annual average growth71163Detection of one of the following antibodies (of 1 or more class or isotype) in the assessment or diagnosis of coeliac disease or other gluten hypersensitivity syndromes and including a service described in item 71066 (if performed): a) Antibodies to gliadin; or b) Antibodies to endomysium; or c) Antibodies to tissue transglutaminase; - 1 test 24.7545,768$970,20944,542–13.0%71164Two or more tests described in 71163 and including a service described in 71066 (if performed)39.90398,442$13,627,707382,97113.4%Recommendation 1Add explanatory notes to the item descriptor for 71163. The following wording is to be added: ‘Serology is not useful in patients shown not to carry the at-risk alleles'. Repeat testing in patients for who antibodies have not been detected is not recommended unless a change in clinical situation has occurred.’ The Department monitor the repeat testing for these tests.The Department to commission a health technology assessment and/or costing analysis on diagnosing and treating coeliac disease that includes diagnosis of coeliac disease and endoscopy combined with other pathology tests and genetic testing of coeliac disease.Table SEQ Table \* ARABIC 4. Current and proposed item descriptors for items 71163 and 71164ItemCurrent item descriptorProposed item descriptor71163Detection of one of the following antibodies (of 1 or more class or isotype) in the assessment or diagnosis of coeliac disease or other gluten hypersensitivity syndromes and including a service described in item 71066 (if performed): a) Antibodies to gliadin; or b) Antibodies to endomysium; or c) Antibodies to tissue transglutaminase; - 1 testDetection of one of the following antibodies (of 1 or more class or isotype) in the assessment or diagnosis of coeliac disease or other gluten hypersensitivity syndromes and including a service described in item 71066 (if performed): a) Antibodies to gliadin; or b) Antibodies to endomysium; or c) Antibodies to tissue transglutaminase.Explanatory notes:Serology is not useful in patients shown not to carry the at-risk alleles. Repeat testing in patients for who antibodies have not been detected is not recommended unless a change in clinical situation has occurred.71164Two or more tests described in 71163 and including a service described in 71066 (if performed)Two or more tests described in 71163 and including a service described in 71066 (if performed) (item is subject to rule 25)Rationale 1During the financial year 2010–2011, the total benefits paid for 71163 and 71164 was $1.7?million and $8.4 million, respectively; in 2014–2015, the total benefits were $970,209 and $13.6 million. The Committee recognises that there has been significant growth in the utilisation of item 71164 for two or more antibodies over the last 5 years, while utilisation of item 71163 has declined.This increase in utilisation could be due to the increased number of awareness campaigns by certain organisations that may be overstating the prevalence of coeliac disease within the Australian population. The maximum estimated rate of 0.5% of coeliac disease within the Australian population yields 105,000 people and there are approximately 400,000 people being tested per year. An Australian study estimates the prevalence of coeliac disease to be 1.2% in men and 1.9% in women.PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5BbmRlcnNvbjwvQXV0aG9yPjxZZWFyPjIwMTM8L1llYXI+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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5BbmRlcnNvbjwvQXV0aG9yPjxZZWFyPjIwMTM8L1llYXI+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ADDIN EN.CITE.DATA [2]During the financial year 2014–2015, women aged 25–34 years were the main users of item 71163 and accounted for 5,155 services compared with 1,825 services for men in the same group. Women aged 25–34 years were the main users of item 71164. This demographic group accounted for 50,000 services compared with men in this age group, who accounted for 20,000?services. The US Preventive Services Task Force Recommendation Statement says the current evidence is insufficient on the effectiveness of screening for coeliac disease in asymptomatic patients and patients at increased risk for coeliac disease.PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5CaWJiaW5zLURvbWluZ288L0F1dGhvcj48WWVhcj4yMDE3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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5CaWJiaW5zLURvbWluZ288L0F1dGhvcj48WWVhcj4yMDE3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ADDIN EN.CITE.DATA [3] Diagnosing coeliac disease in symptomatic patients (older than 2 years) comprises test tissue transglutaminase IgA, followed by intestinal biopsy.PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5BbmRlcnNvbjwvQXV0aG9yPjxZZWFyPjIwMTM8L1llYXI+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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5BbmRlcnNvbjwvQXV0aG9yPjxZZWFyPjIwMTM8L1llYXI+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ADDIN EN.CITE.DATA [2]The main requesters of items 71163 and 71164 are GPs and gastroenterologists; about 50% of requests from are GPs for item 71163 and 18% from gastroenterologists, while 72% of requests are GPs for item 71164 and 9% are from gastroenterologists. There is a state variation in the utilisation of item 71163, with 49 requests per 100,000 people in SA for the FY 2014–15 compared with 421 and 486 requests per 100,000 people in WA and ACT, respectively.During the financial year 2014–2015, the number of services received by patients for item 71163 were as follows: 43,009 patients received the service once, 1040 patients received the service twice, 58 patients received the service three times and 11 patients received the service four times. The number of services received by patients for item 71164 were: 370,767 patients received the service once, 13,337 patients received the service twice, 970 patients received the service three times and 126 patients received the service four times.The Committee recognises that coeliac disease is commonly asymptomatic. However, unrecognised coeliac disease can lead to significant health problems such as iron deficiency and osteoporosis. Coeliac disease can develop at any age and does not have a detectable preclinical state.The Committee also recognises that two antibody tests increase sensitivity for the diagnosis, especially in patients with low IgA levels (low IgA levels are also associated with a higher rate of coeliac disease). The uncertainties include whether the increased yield in detection justifies the increased cost of testing, increased because:two tests now often done instead of one, and such testing is no longer restricted to patients with symptoms or signs of malabsorption alone (associated iron deficiency and osteoporosis, for example). A health technology assessment or a review of the literature will be required to provide the prevalence and natural history data for the cost–benefit analysis.The proposed changes will have no direct effect on patients.Genotyping for coeliac disease risk for DQ2 and DQ8: item 71151Table SEQ Table \* ARABIC 5. Item introduction table for item 71151ItemLong item descriptorSchedule feeServices FY?2014–15Benefits FY?2014–15Patient countServices 5-year annual average growth71151Tissue typing for HLA-DR, HLA-DP and HLA-DQ Class II antigens (including any separation of leucocytes) - phenotyping or genotyping of 2 or more antigens$118.8534,208$3,589,47733,36514.1%Recommendation 2Add the following extra wording to the item descriptor for 71151: ‘this item is not to be used for investigation of possible coeliac disease.’Create a new item with the following item descriptor:Tissue typing in coeliac disease: Determination of tissue types (DQ2/DQ8) associated with coeliac disease. The method used needs to be able to resolve both the DQA1* and DQB1* alleles to the four-digit level of resolution, for all the known at-risk alleles of DQ2 and DQ* and exclude common alternative alleles.Table SEQ Table \* ARABIC 6. Current and proposed item descriptors for item 71151 and new itemItemCurrent item descriptorProposed item descriptor71151Tissue typing for HLA-DR, HLA-DP and HLA-DQ Class II antigens (including any separation of leucocytes) - phenotyping or genotyping of 2 or more antigensTissue typing for HLA-DR, HLA-DP and HLA-DQ Class II antigens (including any separation of leucocytes) - phenotyping or genotyping of 2 or more antigens. This item is not to be used for investigation of possible coeliac disease.New item—Tissue typing in coeliac disease: Determination of tissue types (DQ2/DQ8) associated with coeliac disease. The method used must be able to resolve both the DQA1* and DQB1* alleles to the four-digit level of resolution, for all the known at-risk alleles of DQ2 and DQ* and exclude common alternative allelesRationale 2Item 71151 is used to detect leucocyte antigens and this testing is important in transplanting organs or tissue. The Committee noted that during 2014–15 there was variation in the utilisation of item 71151 across the states and territories, which can possibly be accounted for by public hospital laboratories in Qld and WA performing tissue typing onsite.Genetic testing with HLA DQ2/DQ8 is useful in certain circumstances:A negative test result excludes coeliac disease, as more than 99% of patients with coeliac disease carry one or other of the markers.A positive test is not useful to diagnose coeliac disease because HLA DQ2/DQ8 is present in about 50% of the population.PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5BbmRlcnNvbjwvQXV0aG9yPjxZZWFyPjIwMTM8L1llYXI+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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5BbmRlcnNvbjwvQXV0aG9yPjxZZWFyPjIwMTM8L1llYXI+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ADDIN EN.CITE.DATA [2]The Committee recognises that testing for coeliac disease-related HLA-DQ typing (i.e. for DQ2 and DQ8) is likely to be included in requests for item 71151 and therefore recommended that a new item be created for this indication. This has been considered before by the Pathology Service Advisory Committee (PSAC). PSAC advised that item 71151 is at risk of inappropriate use by referrers, by possibly using a positive test result for HLA to imply the presence of possible coeliac disease; PSAC suggested restricting this item to promote appropriate use. The Committee recognises there may be changes in clinical guidelines that may influence the requesting of this test, which could lead to increased testing.As these are tests of a person’s DNA, the results should not change during their lifetime. However, testing a second time to confirm unexpected results may occasionally be required, or if results from previous testing are not available.The Committee recognises that the current Schedule does not reflect current clinical practice and proposes that a new item be created for this test to be remunerated within the MBS (at the same fee for item 71151).Specific immunoglobulin E antibodies: item 71079Table SEQ Table \* ARABIC 7. Item introduction table for item 71079ItemLong item descriptorSchedule feeServices FY?2014–15Benefits FY?2014–15Patient countServices 5-year annual average growth71079Detection of specific immunoglobulin E (IgE) antibodies to single or multiple potential allergens, 1 test (Item is subject to rule 25)$26.80201,567$4,615,660191,7017.3%Recommendation 3Create a new item to capture multiple recombinant and purified component allergens.Amend the item descriptor of item 71079 to add the word ‘extracted’.The utilisation of the new item is to be monitored by the Department.The Committee’s proposed changes to item 71079 are presented in the table below.Table SEQ Table \* ARABIC 8. Current and proposed item descriptors for item 71079 and new itemItemCurrent item descriptorProposed item descriptor71079Detection of specific immunoglobulin E antibodies to single or multiple potential allergens, 1 test (Item is subject to rule 25)Detection of specific immunoglobulin E (IgE) antibodies to single or multiple potential extracted allergens.New item—Detection of specific immunoglobulin E (IgE) antibodies to single or multiple recombinant and purified component allergens for allergens.Explanatory note:This test is to be used in specific patient populations such as those who have food allergies, insect venom allergies and aeroallergies.Rationale 3Item 71079 is an allergen-specific IgE antibody test used to screen for an allergy to a specific allergen, for example, the subcomponents of peanut such as Ara h?2. The Committee recognises the importance of allergen testing and considered the literature when making its recommendation for this item.The clinical utility of recombinant and purified allergen testing was considered when the Committee was proposing recommendations for this item. Recombinant and purified allergen markers are considered to be more predictive of disease than previously available allergen extracts, hence the recommendation for introduction of the new item.The issues regarding purified and recombinant allergens (sometimes referred to as component resolved diagnostics) are as follows:In about the last 5 years a number of purified or recombinant allergens have been identified that can improve the performance of testing. Examples include Ara h 2, Ara h 8, Ara h 9 (these three for peanut), ‘alpha-gal’ (for meat allergy), and omega-gliadin (for exercise-induced wheat allergy)—the latter two are often used in workup of idiopathic anaphylaxis, a rare but serious consideration.Recombinant allergen testing has greater clinical utility than routine allergy testing, in a small number of patients. The current item 71079 is used for both these newer allergen tests and the older less predictive allergen testing.There are issues regarding the overuse of allergy testing (including allergen extracts), including:The older / more established testing to allergen extracts are noted to be imperfect and inferior to skin prick testing when performed by a specialist allergist. Access to allergist review is limited to metropolitan areas. Blood tests to allergen extracts can therefore be helpful for patients in regional and rural areas, and addresses the access gap.The potential for overuse of blood tests for allergies is high. One solution would be to restrict to specialists. However, there are not enough allergists to review all these patients. Many requests include an excessive number of allergens, with a diminishing yield from such ‘fishing trips’.The test is difficult to restrict and there would be some patients, including some children, who would benefit from having multiple allergens tested on the one sample, although this is a very small group. This item could be restricted to a specialist only MBS number; nonetheless this would be a great challenge for the laboratory and not a solution for this item. Hence, the proposal to create a new item to capture the population—including patient populations who have food allergies, insect venom allergies and aeroallergies—that would require this test and that this new item be monitored to see requesting patterns.Antinuclear antibodies tests: item 71097Table SEQ Table \* ARABIC 9. Item introduction table for item 71097ItemLong descriptorSchedule feeServices FY?2014–15Benefits FY?2014–15Patient countServices 5-year annual average growth71097Antinuclear antibodies - detection in serum or other body fluids, including quantitation if required$24.45525,936$10,964,607469,2944.4%Recommendation 4The Committee proposes the following:Change the item descriptor to remove the wording ‘or other body fluids’ from the current item descriptorDevelop a targeted education program on the clinical appropriateness of antinuclear antibodies for GPs and rheumatologists. This education program should inform requesters of the changes and the appropriate guidelines for testing. This recommendation aligns with a separate proposal for antinuclear antibody training to be a requirement for rheumatologists and the as-yet unpublished guidelines on use of antinuclear antibodies.Table SEQ Table \* ARABIC 10. Current and proposed item descriptors for item 71097ItemCurrent item descriptorProposed item descriptor71097Antinuclear antibodies - detection in serum or other body fluids, including quantitation if requiredAntinuclear antibodies - detection in serum, including quantitation if required Rationale 4Item 71097 is the antinuclear antibody test used to help confirm or exclude the diagnosis of systemic rheumatic disease. Antinuclear antibodies are associated with a number of autoimmune diseases but are used specifically to diagnose and classify disease in patients presenting with clinical symptoms or other laboratory results suggesting rheumatic disease. Antinuclear antibody tests are rarely used in isolation and often used early in the evaluation of patients to better direct investigations. ADDIN EN.CITE <EndNote><Cite><Author>O’Sullivan</Author><Year>2013</Year><RecNum>5</RecNum><DisplayText> [4]</DisplayText><record><rec-number>5</rec-number><foreign-keys><key app="EN" db-id="05trxwd9pxaf9oeezd6xrte0pftav5ade0ww" timestamp="1496122873">5</key></foreign-keys><ref-type name="Journal Article">17</ref-type><contributors><authors><author>O’Sullivan, M.</author><author>McLean-Tooke, A.</author><author>Loh, R.</author></authors></contributors><titles><title>Antinuclear antibody test</title><secondary-title>Australian Family Physician</secondary-title></titles><periodical><full-title>Australian Family Physician</full-title></periodical><pages>718-721</pages><volume>42</volume><keywords><keyword>australian, family, physician, afp, 2013, october, antinuclear antibodies, immune system diseases, autoimmune disease</keyword></keywords><dates><year>2013</year></dates><publisher>The Royal Australian College of General Practitioners (RACGP)</publisher><urls><related-urls><url> October 2017</access-date></record></Cite></EndNote> [4] During the financial year 2014–2015, the number of services received by patients were as follows: 424,153 patients received the service once, 38,890 patients received the service twice, and 5763 patients received the service three times. The number of patients receiving the service more than three times during 2014–15 was 1881.When present and associated with disease, these antibodies remain stable for many years. Repeat testing to confirm unexpected results is appropriate, but these antibodies are not validated for monitoring disease activity. The Committee decided to remove body fluids from the item descriptor because there is no clinical reason to perform an antinuclear antibody test on body fluids. Testing for the presence of antinuclear antibodies in samples other than peripheral blood is not recommended because there are no clinically validate indications for such testing, and reference intervals cannot be established for such samples, which precludes useful interpretation of such results.When diseases for which these antibodies are associated are present, the antibodies normally precede the disease presentation by months to years. Repeating testing in early stages of a patient’s presentation to see if there are progression of such antibodies therefore is almost always unnecessary.The proposed changes will have no direct effect on patients.Double-stranded DNA antibodies: item 71099Table SEQ Table \* ARABIC 11. Item introduction table for item 71099ItemLong item descriptorSchedule feeServices FY?2014–15Benefits FY?2014–15Patient countServices 5-year annual average growth71099Double-stranded DNA antibodies - quantitation by 1 or more methods other than the Crithidia method$26.50195,681$4,419,881168,3507.9%Recommendation 5The Committee proposes the following:Remove the wording ‘other than the Crithidia method’ from the item descriptor.Table SEQ Table \* ARABIC 12. Current and proposed item descriptors for item 71099ItemCurrent item descriptorProposed item descriptor71099Double-stranded DNA antibodies - quantitation by 1 or more methods other than the Crithidia methodDouble-stranded DNA antibodies - quantitation by 1 or more methodsRationale 5Item 71099 is the anti-double stranded DNA test used to help diagnose systemic lupus erythematosus in patients who have a positive result on an antinuclear antibody test and have presenting clinical symptoms. There is an equal utilisation of item 71099 across the states and territories. The use of Crithidia as a substrate for the detection of antibodies to double stranded DNA is a valid methodology, and not inferior to some of the alternate assay methodologies in current use.The proposed changes have no direct effect on patients.Antibodies to extractable nuclear antigens: items 71101 and 71103Table SEQ Table \* ARABIC 13. Item introduction table for items 71101 and 71103ItemLong item descriptorSchedule feeServices FY?2014–15Benefits FY?2014–15Patient countServices 5-year annual average growth71101Antibodies to 1 or more extractable nuclear antigens - detection in serum or other body fluids$17.40151,483$2,235,329139,0298.6%71103Characterisation of an antibody detected in a service described in item 71101 (including that service)$52.0535,313$1,568,13029,50413.4%Recommendation 6Amend item descriptor of item 71101 to remove the words ‘or other body fluids’.Items 71101 and 71103 to be monitored by the Department. Laboratories who claim a ratio of 71103:71101 greater than one-third should be audited.Rationale 6Items 71101 and 71103 are tests used to detect antibodies for extractable nuclear antigens (ENA); these tests are used to help diagnose and distinguish between autoimmune disorders such as mixed connective tissue disease, Sj?gren's syndrome and systemic lupus erythematosus. This test has been available for more than 30 years. Autoantibody testing is only necessary when a person presents with symptoms that suggest an autoimmune disorder. The state variation for items 71101 and 71103 are as follows: NSW has the highest utilisation of item 71101 with 832 per 100,000 compared with 258 per 100,000 people in the NT. Utilisation of item 71103 is 644 per 100,000 in ACT while in Vic the utilisation is 82 per 100,000. For item 71101, the number of services received by patients during 2014–2015 are as follows: 128,622 patients received the service once, 8989 had the service twice, and 1217 patients received the service three times; 329 patients received the service four or more times. For item 71103, a total of 24,952 patients received the service once, 3735 patients received the service twice, and 672 patients received the service three times; 222 patients received the service four or more times.The Committee recognises that item 71101 might be used as a monitoring test in clinical practice and is being repeated unnecessarily. Item 71101 should not be repeated until clinical conditions change. Changes in long-lived antibodies are gradual, requiring several months to develop, resolve or alter, and in most cases these antibodies remain unchanged for several years. The Committee recommended that the Department monitor items 71101 and 71103 and audit laboratories when the ratio of 71103:71101 is greater than one-third. These antibodies are relatively uncommon, so most testing will not detect them. Item 71103 is for the characterisation of antibodies after detection, and so should be required in a minority of samples.There is no clinical reason to perform an extractable nuclear antibody test on body fluids. Testing for the presence of extractable nuclear antibodies in samples other than peripheral blood is not recommended because there are no clinically validated indications for such testing, and reference intervals cannot be established for such samples, which precludes useful interpretation of such results.The proposed changes have no direct effect on patients.Quantitation of complement components: items 71083, 71085, 71087, 71089, 71091 and 71093Table SEQ Table \* ARABIC 14. Item introduction table for items 71083, 71085, 71087, 71089, 71091 and 71093ItemLong item descriptorSchedule feeServices FY?2014–15Benefits FY?2014–15Patient countServices 5-year annual average growth71083Quantitation of complement components C3 and C4 or properdin factor B – 1?test$20.154,649$79,0873,38220.6%710852 tests described in item 71083$28.9595,153$2,336,44077,1737.6%710873 or more tests described in item 71083$37.70329$10,53227121.8%71089Quantitation of complement components or breakdown products of complement proteins not elsewhere described in an item in this Schedule - 1 test (Item is subject to rule 6)$29.15540$13,3255153.7%710912 tests described in item 71089 (Item is subject to rule 6)$52.85133$5,94113236.5%710933 or more tests described in item 71089 (Item is subject to rule 6)$76.4524$1,51426–36.7%Recommendation 7Remove the properdin and factor B from items 71083–71087.Delete item 71087.Remove the wording specifying ‘breakdown products of complement proteins’ from the item descriptors for items 71089–71093.Add the wording ‘other than C3 or C4’ to the item descriptors for items 71089–71093.The Committee’s proposed changes are summarised in the table below.Table SEQ Table \* ARABIC 15. Current and proposed item descriptors for items 71083, 71085, 71087, 71089, 71091 and 71093Item noCurrent descriptorNew proposed descriptor71083Quantitation of complement components C3 and C4 or properdin factor B - 1 testQuantitation of complement components C3 or C4710852 tests described in item 71083Quantitation of complement components C3 and C4 (2 tests)710873 or more tests described in item 71083Delete71089Quantitation of complement components or breakdown products of complement proteins not elsewhere described in an item in this Schedule - 1 testQuantitation of complement components other than C3 or C4 (1 test)710912 tests described in item 710892 tests described in item 71089710933 or more tests described in item 710893 or more tests described in item 71089Rationale 7Items 71083–71093 are tests used to determine whether deficiencies or abnormalities in the complement system contribute to a person’s condition. Complement tests are used to monitor people diagnosed with an autoimmune disorder (such as rheumatoid arthritis or lupus) to see if treatment is working; C3 and C4 are the most commonly measured complement components. The main requestors of these tests are rheumatologists and immunologists.The proposed changes reflect that knowledge and utility of more complex testing has advanced in medicine, with many new applications being relevant to the investigation of disease. The proposed changes remove obsolescence from the tests for quantitation of complement components and bring the tests into line with these advances. For example, properdin and factor B no longer reflect clinical practice, and item 71087 is no longer required with removal of these components. The combined testing for C3 and C4 results in loss of ability to track the items separately. Therefore the Committee recommends that the descriptors for items 71803 and 71805 be changed to enable tracking of both items.The proposed changes have no direct effect on patients.Antibodies to tissue antigens: items 71119, 71121, 71123 and 71125Table SEQ Table \* ARABIC 16. Item introduction table for items 71119, 71121, 71123 and 71125ItemLong item descriptorSchedule feeServices FY?2014–15Benefits FY?2014–15Patient countServices 5-year annual average growth71119Antibodies to tissue antigens not elsewhere specified in this Table - detection, including quantitation if required, of 1 antibody$17.35146,135$2,157,532135,7816.3%71121Detection of 2 antibodies specified in item 71119$20.8021,047$370,27720,3525.1%71123Detection of 3 antibodies specified in item 71119$24.2514,633$300,22214,3120.3%71125Detection of 4 or more antibodies specified in item 71119$27.657989$187,265737913.0%Recommendation 8The Committee proposes the following:Remove the wording ‘or more’ from the item descriptor for 71125.Add a new item for five or more tests for antibodies.The Committee’s proposed changes are summarised in the table below.Table SEQ Table \* ARABIC 17. Current and proposed item descriptors for items 71119, 71121, 71123, 71125ItemCurrent item descriptorProposed item descriptor71119Antibodies to tissue antigens not elsewhere specified in this Table - detection, including quantitation if required, of 1 antibodyRemain unchanged71121Detection of 2 antibodies specified in item 71119Remain unchanged71123Detection of 3 antibodies specified in item 71119Remain unchanged71125Detection of 4 or more antibodies specified in item 71119Detection of 4 antibodies specified in item 7111971126 (new item)Detection of 5 or more antibodies specified in item 71119. Rationale 8Items 71119, 71121, 71123 and 71125 are tests used to detect antibodies for autoimmune diseases that are not already accounted for by an individual item number within the MBS; these diseases include scleroderma and myositis. Currently, there is no item number to capture the clinical population that requires a test for five or more antibodies to tissue antigens. There is a small but significant clinical population that will require four or more antibodies (see benefits paid). The Committee recognises that creating a new item will allow for better data collection on this population to find out what proportion of the population requires five or more antibodies. Certain patients have a defined autoimmune disease, and testing for more antibodies allows for profiling of these patients to discover the underlying cause of the disease.Several antigens are not specified elsewhere in the table, such as myositis- and scleroderma-associated antibodies that would be included under this item and are considered clinically appropriate and valid tests. Extending testing to include five or more antibodies would address the access gap for this small patient cohort, as these tests are expensive but are considered clinically relevant. This Committee recommendation focuses on enabling data collection on the use of the test. Antibodies to tissue antigens: item 71165Table SEQ Table \* ARABIC 18. Item introduction table for item 71165ItemLong item descriptorSchedule feeServices FY?2014–15Benefits FY?2014–15Patient countServices 5-year annual average growth71165Antibodies to tissue antigens (acetylcholine receptor, adrenal cortex, heart, histone, insulin, insulin receptor, intrinsic factor, islet cell, lymphocyte, neuron, ovary, parathyroid, platelet, salivary gland, skeletal muscle, skin basement membrane and intercellular substance, thyroglobulin, thyroid microsome or thyroid stimulating hormone receptor) - detection, including quantitation if required, of 1 antibody (Item is subject to rule 6)$34.55128,207$4,391,757107,56410.0%Recommendation 9The Committee proposed the following:Amend the item descriptor for 71165 to remove thyroid antibodies and salivary gland.Remove salivary gland from the item descriptor.Table SEQ Table \* ARABIC 19. Current and proposed item descriptors for item 71165ItemCurrent item descriptorProposed item descriptor71165Antibodies to tissue antigens (acetylcholine receptor, adrenal cortex, heart, histone, insulin, insulin receptor, intrinsic factor, islet cell, lymphocyte, neuron, ovary, parathyroid, platelet, salivary gland, skeletal muscle, skin basement membrane and intercellular substance, thyroglobulin, thyroid microsome or thyroid stimulating hormone receptor) - detection, including quantitation if required, of 1 antibody (Item is subject to rule 6)Antibodies to tissue antigens (acetylcholine receptor, adrenal cortex, heart, histone, insulin, insulin receptor, intrinsic factor, islet cell, lymphocyte, neuron, ovary, parathyroid, platelet, skeletal muscle, skin basement membrane and intercellular substance) - detection, including quantitation if required, of 1 antibody (Item is subject to rule 6)Rationale 9The Committee recommended removing thyroid antibodies from the item descriptor of 71165, as there is a new item number proposed for thyroid antibodies within the pathology section of the MBS. The Committee recommended the removal of salivary gland from the item 71165, as this is no longer considered a clinically useful test. The proposed changes will have no direct effect on patients.Quantitation of immunoglobulin E: items 71075 and 71077Table SEQ Table \* ARABIC 20. Item introduction table for item 71075 and 71077ItemLong item descriptorSchedule feeServices FY?2014–15Benefits FY?2014–15Patient countServices 5-year annual average growth71075Quantitation of immunoglobulin E (total), (IgE) 1 test. (Item is subject to rule 25)$23.00133,831$2,619,828127,9015.5%71077Quantitation of immunoglobulin E (total) (IgE) in the follow up of a patient with proven immunoglobulin-E-secreting myeloma, proven congenital immunodeficiency or proven allergic bronchopulmonary aspergillosis, 1 test. (Item is subject to rule 25)$27.052$43214.9%Recommendation 10Consolidate item 71077 into item 71075.Change the fee of item 71075 to the same fee as item 71077. Table SEQ Table \* ARABIC 21. Current and proposed item descriptors for items 71075 and 71077ItemCurrent item descriptorProposed item descriptor71075Quantitation of immunoglobulin E (total), (IgE) 1 test. (Item is subject to rule 25)Quantitation of immunoglobulin E (total), (IgE) 1 test. (Item is subject to rule 25)Explanatory note:Repeat testing of IgE in the monitoring of allergy is of no clinical use.71077Quantitation of immunoglobulin E (total) (IgE) in the follow up of a patient with proven immunoglobulin-E-secreting myeloma, proven congenital immunodeficiency or proven allergic bronchopulmonary aspergillosis, 1 test. (Item is subject to rule 25)DeleteRationale 10The Committee noted the low usage of item 71077 is due to the difficulty in the coding, with item 71077 being billed as item 71075. Items 71075 and items 71077 are essentially the same tests but are used for different indications. Deleting item 71077 and consolidating it into item 71075 will simplify the MBS and avoid confusion in terms of claiming.Monitoring total IgE levels is appropriate for allergic bronchopulmonary aspergillosis and IgE-secreting myeloma (the latter is extremely rare), and such testing should be able to be accommodated with four tests per year. During the financial year 2014–2015, a total of 123,188 patients received service for item 71075 once, 4522 patients received the service twice, 386?patients received the service three times and 97 patients received the service four times. The maximum number of times a patient received a service for item 71075 was 12 during 2014–2015; 77 patients received a service for item 71075 more than four times.There is no clinical utility in testing more than four times within a 12-month period. The proposed changes will have no direct effect on patients.Quantitation of total immunoglobulin A: item 71066Table SEQ Table \* ARABIC 22. Item introduction table for item 71066ItemLong item descriptorSchedule feeServices FY?2014–15Benefits FY?2014–15Patient countServices 5-year annual average growth71066Quantitation of total immunoglobulin A by any method in serum, urine or other body fluid – 1 test$14.555150$63,5494867–5.5%Recommendation 11Remove the words ‘urine or other body fluid’ from item 71066.Table SEQ Table \* ARABIC 23. Current and proposed item descriptors for item 71066ItemCurrent item descriptorProposed item descriptor71066Quantitation of total immunoglobulin A by any method in serum, urine or other body fluid – 1 testQuantitation of total immunoglobulin A by any method in serum – 1 testRationale 11This test should not be performed in urine or other body fluid. There is no clinical reason to perform an IgA test on body fluids. Testing for the presence of extractable IgA in samples other than peripheral blood is not recommended because there are no clinically validated indications for such testing, and reference intervals cannot be established for such samples, which precludes useful interpretation of such results.The proposed change does not have a direct effect on patients.Quantitation of total immunoglobulin M: item 71072Table SEQ Table \* ARABIC 24. Item introduction table for item 71072ItemLong item descriptorSchedule feeServices FY?2014–15Benefits FY?2014–15Patient countServices 5-year annual average growth71072Quantitation of total immunoglobulin M by any method in serum, urine or other body fluid - 1 test$14.551004$12,340708–17.7%Recommendation 12Remove the words ‘urine or other body fluid’ from item 71072.Table SEQ Table \* ARABIC 25. Current and proposed item descriptors for item 71072ItemCurrent item descriptorProposed item descriptor71072Quantitation of total immunoglobulin M by any method in serum, urine or other body fluid - 1 testQuantitation of total immunoglobulin M by any method in serum - 1 testRationale 12This test should not be performed in urine or other body fluid. There is no clinical reason to perform an IgM test on body fluids. Testing for the presence of extractable IgM in samples other than peripheral blood is not recommended because there are no clinically validated indications for such testing, and reference intervals cannot be established for such samples, which precludes useful interpretation of such results.The proposed change does not have a direct effect on patients.Quantitation of total immunoglobulin D: item 71074Table SEQ Table \* ARABIC 26. Item introduction table for item 71074ItemLong item descriptorSchedule feeServices FY?2014–15Benefits FY?2014–15Patient countServices 5-year annual average growth71074Quantitation of total immunoglobulin D by any method in serum, urine or other body fluid - 1 test$14.55250$3,054226–0.8%Recommendation 13Remove the words ‘urine or other body fluid’ from item 71074.Table SEQ Table \* ARABIC 27. Current and proposed item descriptors for item 71074ItemCurrent item descriptorProposed item descriptor71074Quantitation of total immunoglobulin D by any method in serum, urine or other body fluid - 1 testQuantitation of total immunoglobulin D by any method in serum - 1 testRationale 13This test should not be performed in urine or other body fluid. There is no clinical reason to perform an IgD test on body fluids. Testing for the presence of extractable IgD in samples other than peripheral blood is not recommended because there are no clinically validated indications for such testing, and reference intervals cannot be established for such samples, which precludes useful interpretation of such results.The proposed change does not have a direct effect on patients.Cryoglobulins or cryofibrinogen: item 71064Table SEQ Table \* ARABIC 28. Item introduction table for item 71064ItemLong item descriptorSchedule feeServices FY?2014–15Benefits FY?2014–15Patient countServices 5-year annual average growth71064Detection and quantitation of cryoglobulins or cryofibrinogen - 1 or more tests$20.757302$126,81065797.5%Recommendation 14Increase the MBS fee for item 71064.The Committee has referred this recommendation to the Pathology Business Group.Rationale 14Item 71064 is a test used to determine whether symptoms such as sensitivity of extremities to cold is due to the presence of abnormal proteins called cryoglobulins. Cryoglobulins tend to clump together when exposed to cold temperatures and dissolve when exposed to warm temperatures; they are present in high levels in abnormal protein production in some autoimmune, infectious and blood diseases.Currently, the MBS fee does not reflect the costs associated with this test. Cryoglobulins are very expensive to collect and transport; this item is often billed with 71062. When a patient attends a laboratory the ‘hot box’ equipment is available; this is particularly important issue for remote patients who have to travel to the laboratory.The analysis includes storage of samples at different temperatures and then determination of proportional precipitation day(s) later. Cryoglobulin testing involves the collection of blood in a pre-warmed tube and keeping the blood sample at body temperature during preparation for testing. If samples are not kept at body temperature after venepuncture until analysis, the results will vary widely.The complexity of this ‘pre-analytical’ phase requires significant resources—equipment, staff and education—factors not covered by routine patient episode initiation or the current fee for item 71064. Increasing the fee for item 71064 will allow for correct collection and quality results for patients.The proposed changes will improve access for patients, reduce rates of unnecessary venepuncture, improve how blood samples are collected and increase accuracy of test results.Rheumatoid factor: item 71106Table SEQ Table \* ARABIC 29. Item introduction table for item 71106ItemLong item descriptorSchedule feeServices FY?2014–15Benefits FY?2014–15Patient countServices 5-year annual average growth71106Rheumatoid factor - detection by any technique in serum or other body fluids, including quantitation if required$11.30151,083$1,451,776137,2041.6%Recommendation 15Remove the words ‘or other body fluids’ from the item descriptor of item 71106.Develop an education program aimed at rheumatologists on how often to request this test in patients with known rheumatoid disease.Rationale 15Item 71106 is a test used to determine the levels of autoantibody rheumatoid factor. Rheumatoid factor is elevated in chronic and acute inflammation and can be used to monitor inflammation in rheumatoid arthritis (RA).During the financial year 2014–2015, for item 71106, a total of 126,263 patients received the service once, 9214 patients received the service twice, 1359 patients received the service three times and 314 patients received the service four times. The maximum number of services received by a single patient was 14 and approximately 212 patients received the service more than four times in the year.Other biomarkers are also available which are superior for disease monitoring such as C-reactive protein (CRP) or swollen and/or tender joint count. The Committee used guidelines for RA to extrapolate from the European League Against Rheumatism management guidelines, which state that ‘monitoring should be frequent in active disease (every 1–3 months); if there is no improvement by at most 3 months after the start of treatment or the target has not been reached by 6 months, therapy should be adjusted.’PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5TbW9sZW48L0F1dGhvcj48WWVhcj4yMDE3PC9ZZWFyPjxS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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5TbW9sZW48L0F1dGhvcj48WWVhcj4yMDE3PC9ZZWFyPjxS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ADDIN EN.CITE.DATA [5]The Committee notes that the guidelines refer to monitoring of biomarkers of disease activity, which includes patient pain, patient function, number of swollen or tender joints, ultrasound assessment of blood flow around joints, and blood tests for inflammation. The tests the Committee has reviewed are not markers of activity but are rather markers of diagnostic utility and prognostic impact. Therefore the antibodies referred to should be tested less than the markers of activity.The Committee proposed a targeted education program for rheumatologists on utility of the test and alternative biomarkers of disease activity.The Committee proposes to remove other body fluids from the item descriptor because testing in samples other than peripheral blood is not recommended because there are no clinically validated indications for such testing, and reference intervals cannot be established for such samples, which precludes useful interpretation of such results.Restricting testing of rheumatoid factor will have no direct impact on patients but may indirectly reduce rates of unnecessary venepuncture, reduce rates of false-positive results and subsequently reduce patient anxiety.Antibody to cardiolipin: items 71180, 71183, 71186Table SEQ Table \* ARABIC 30. Item introduction table for items 71180, 71183, 71186ItemLong item descriptorSchedule feeServices FY?2014–15Benefits FY?2014–15Patient countServices 5-year annual average growth71180Antibody to cardiolipin or beta-2 glycoprotein I detection, including quantitation if required; one antibody specificity (IgM or IgG)$34.5512,087$354,64311,2390.3%71183Detection of two antibodies described in item 71180$47.4537,334$1,500,99935,1573.3%71186Detection of three or more antibodies described in item 71180$60.3027,236$1,397,53525,4746.9%Recommendation 16Amend the wording of the item descriptor of 71180 to include IgA.Limit this item by restricting it to four tests within a 12-month period.Rationale 16Items 71180, 71183 and 71186 are tests for beta-2 glycoprotein I and cardiolipin antibodies; testing for these antibodies is used to help diagnose antiphospholipid syndrome. Beta-2 glycoprotein and cardiolipin antibody tests detect the presence of three classes: IgG, IgM and/or IgA. IgA testing for beta-2 glycoprotein I antibody and cardiolipin has superior positive predictive value than IgM testing for the same antigens. IgG antibodies are more prevalent, so IgG antibodies have a higher overall sensitivity than IgA antibodies. IgM testing is present in 71180, but IgA is not, and should be included in this item. The clinical utility of IgM cardiolipin antibodies is being debated internationally, but the evidence is not definite, and if published guidelines for antiphospholipid syndrome criteriaPEVuZE5vdGU+PENpdGU+PEF1dGhvcj5NaXlha2lzPC9BdXRob3I+PFllYXI+MjAwNjwvWWVhcj48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ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5NaXlha2lzPC9BdXRob3I+PFllYXI+MjAwNjwvWWVhcj48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ADDIN EN.CITE.DATA [6] are followed, this is rarely a problem. IgM testing should remain in the item while it is still being mentioned in international guidelines.Table SEQ Table \* ARABIC 31. Current and proposed item descriptors for item 71180ItemCurrent item descriptorProposed item descriptor71180Antibody to cardiolipin or beta-2 glycoprotein i detection, including quantitation if required; one antibody specificity (IgG or IgM)Antibody to cardiolipin or beta-2 glycoprotein I detection, including quantitation if required; one antibody specificity (IgG or IgM or IgA) item subject to rule 25Free kappa and lambda light chains: item 71200Table SEQ Table \* ARABIC 32. Item introduction table for item 71200ItemLong item descriptorSchedule feeServices FY?2014–15Benefits FY?2014–15Patient countServices 5-year annual average growth71200Detection and quantitation, if present, of free kappa and lambda light chains in serum for the diagnosis or monitoring of amyloidosis, myeloma or plasma cell dyscrasias.$59.60103,074$5,197,21752,27727.6%Recommendation 17Amend the item descriptor by including the wording: ‘this test is not to be used for the diagnosis or monitoring of lymphoma’.Table SEQ Table \* ARABIC 33. Current and proposed item descriptors for item 71200ItemCurrent item descriptorProposed item descriptor71200Detection and quantitation, if present, of free kappa and lambda light chains in serum for the diagnosis or monitoring of amyloidosis, myeloma or plasma cell dyscrasias.Detection and quantitation, if present, of free kappa and lambda light chains in serum for the diagnosis or monitoring of amyloidosis, myeloma or plasma cell dyscrasias. This test is not to be used for the diagnosis or monitoring of lymphoma.Rationale 17Item 71200 is serum free light-chain testing used to help diagnose plasma cell disorders (dyscrasias) including myeloma and primary amyloidosis. The utilisation of item 71200 appears to be equal across the states and territories. The Committee recognises that the utilisation of item 71200 is increasing. This is a test mainly requested by haematologists. This item cannot be restricted within a 12-month period, as some patients are treated with particular dialysis therapy. Such patients will require this test every time they undergo dialysis. The Committee recommends a change to the item descriptor wording to specifically exclude the use of this test in lymphoma to reinforce that the clinical utility of these tests are in the assessment of plasma cell disorders only. Lymphoma is specifically excluded from this item, as the diagnosis and management of lymphoma does not require measurement of light chains.Items to be deletedRecommendation 18The following items are to be deleted from the MBS as the items are obsolete and are no longer used in clinical practice. These items are not supported by current treatment strategies.Table SEQ Table \* ARABIC 34. Items to be deletedItemItem descriptorSchedule fee ($)Services (2014–15)71095Quantitation of serum or plasma eosinophil cationic protein, or both, to a maximum of 3 assays in 1 year, for monitoring the response to therapy in corticosteroid treated asthma, in a child aged less than 12 years40.558371096A test described in item 71095 if rendered by a receiving APP, (Item is subject to rule 18)40.55371137Quantitation of cell-mediated immunity by multiple antigen delayed type hypersensitivity intradermal skin testing using a minimum of 7 antigens, 1 of this item to a maximum of 2 in a 12 month period30.25071203Determination of hlab5701 status by flow cytometry or cytotoxity assay prior to the initiation of abacavir therapy including item 73323 if performed.40.550No changesRecommendation 19The Committee recommends that the MBS items listed in REF _Ref499290802 \h Table 35 do not require amendment, as they are clinically appropriate. Table SEQ Table \* ARABIC 35. MBS items that do not require amendmentItemItem descriptorSchedule fee ($)Services (2014–15)71057Electrophoresis, quantitative and qualitative, of serum, urine or other body fluid all collected within a 28 day period, to demonstrate: (a) protein classes; or (b) presence and amount of paraprotein; including the preliminary quantitation of total protein, albumin and globulin - 1 specimen type32.90266,77071058Examination as described in item 71057 of 2 or more specimen types50.5039,20471059Immunofixation or immunoelectrophoresis or isoelectric focusing of:(a) urine for detection of bence jones proteins; or(b) serum, plasma or other body fluid; and characterisation of a paraprotein or cryoglobulin - examination of 1 specimen type (e.g. serum, urine or csf) 35.65143,43171060Examination as described in item 71059 of 2 or more specimen types44.0524,04371062Electrophoresis and immunofixation or immunoelectrophoresis or isoelectric focussing of CSF for the detection of oligoclonal bands and including if required electrophoresis of the patient's serum for comparison purposes - 1 or more tests44.051,87371068Quantitation of total immunoglobulin G by any method in serum, urine or other body fluid - 1 test14.5518,765710692 tests described in items 71066, 71068, 71072 or 7107422.759,172710713 or more tests described in items 71066, 71068, 71072 or 7107430.95178,80371073Quantitation of all 4 immunoglobulin G subclasses106.1520,20971076A test described in item 71073 if rendered by a receiving APP - 1 test(Item is subject to rule 18)106.152,00971081Quantitation of total haemolytic complement40.553,20371090A test described in item 71089, if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP - 1 test (Item is subject to rule 6 and 18)29.1535771092Tests described in item 71089, other than that described in 71090, if rendered by a receiving APP - each test to a maximum of 2 tests (Item is subject to rule 6 and 18)23.701,07271127Functional tests for lymphocytes - quantitation other than by microscopy of: (a) proliferation induced by 1 or more mitogens; or (b) proliferation induced by 1 or more antigens; or (c) estimation of 1 or more mixed lymphocyte reactions; including a test described in item 65066 or 65070 (if performed), 1 of this item to a maximum of 2 in a 12 month period176.35244711292 tests described in item 71127217.85120711313 or more tests described in item 71127259.351671133Investigation of recurrent infection by qualitative assessment for the presence of defects in oxidative pathways in neutrophils by the nitroblue tetrazolium (nbt) reduction test10.402171134Investigation of recurrent infection by quantitative assessment of oxidative pathways by flow cytometric techniques, including a test described in 71133 (if performed)104.0514471135Quantitation of neutrophil function, comprising at least 2 of the following: (a) chemotaxis; (b) phagocytosis; (c) oxidative metabolism; (d) bactericidal activity; including any test described in items 65066, 65070, 71133 or 71134 (if performed), 1 of this item to a maximum of 2 in a 12 month period207.9598371139Characterisation of 3 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations, including a total lymphocyte count or total leucocyte count by any method, on 1 or more specimens of blood, CSF or serous fluid$104.0553,57071141Characterisation of 3 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations on 1 or more disaggregated tissue specimens197.351,42071143Characterisation of 6 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations for the diagnosis (but not monitoring) of an immunological or haematological malignancy, including a service described in 1 or both of items 71139 and 71141 (if performed), on a specimen of blood, CSF, serous fluid or disaggregated tissue260.0066,14171145Characterisation of 6 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations for the diagnosis (but not monitoring) of an immunological or haematological malignancy, including a service described in 1 or more of items 71139, 71141 and 71143 (if performed), on 2 or more specimens of disaggregated tissues or 1 specimen of disaggregated tissue and 1 or more specimens of blood, CSF or serous fluid424.503,70571146Enumeration of cd34+ cells, only for the purposes of autologous or directed allogeneic haemopoietic stem cell transplantation, including a total white cell count on the pherisis collection104.052,76871147HLA-B27 typing (Item is subject to rule 27)40.5552,95571148A test described in item 71147 if rendered by a receiving APP. (Item is subject to rule 18 and 27)40.553,42071149Complete tissue typing for 4 HLA-A and HLA-B Class I antigens (including any separation of leucocytes), including (if performed) a service described in item 71147108.253,66371153Investigations in the assessment or diagnosis of systemic inflammatory disease or vasculitis - antineutrophil cytoplasmic antibody immunofluorescence (anca test), antineutrophil proteinase 3 antibody (pr-3 anca test), antimyeloperoxidase antibody (mpo anca test) or antiglomerular basement membrane antibody (gbm test) - detection of 1 antibody (item is subject to rule 6 and 23)34.5589,56771154A test described in item 71153, if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP - 1 test.(Item is subject to rule 6, 18 and 23)34.553,03571155Detection of 2 antibodies described in item 7115347.456,38771156Tests described in item 71153, other than that described in 71154, if rendered by a receiving APP each test to a maximum of 3 tests(Item is subject to rule 6, 18 and 23)12.854,32071157Detection of 3 antibodies described in item 71153(item is subject to rule 6 and 23)60.3033,61071159Detection of 4 or more antibodies described in item 71153 (Item is subject to rule 6 and 23)(item is subject to rule 6 and 23)"73.151,94871170Tests described in item 71165, other than that described in 71169, if rendered by a receiving APP – each test to a maximum of 3 tests. (Item is subject to rule 6 and 18.)12.8515,39971189Detection of specific igg antibodies to 1 or more respiratory disease allergens not elsewhere specified.15.501,872711922 items described in item 71189.28.35434711953 or more items described in item 71189.40.0545771198Estimation of serum tryptase for the evaluation of unexplained acute hypotension or suspected anaphylactic event, assessment of risk in stinging insect anaphylaxis, exclusion of mastocytosis, monitoring of known mastocytosis.40.5511,570Source: Department of Human Services, date of processingReferred itemsErythrocyte sedimentation rate (ESR)ESR was a priority item identified for review by the Taskforce following submissions from the Royal College of Pathologists of Australasia (RCPA) and Public Pathology Australia to the Taskforce. The Committee sought input on ESR from both immunology and haematology experts.Table SEQ Table \* ARABIC 36. Item introduction for item 65060ItemLong item descriptorSchedule feeServices FY?2014–15Benefits FY?2014–15Patient countServices 5-year annual average growth65060Haemoglobin, erythrocyte sedimentation rate, blood viscosity -1 or more tests$7.85 175,678$1,153,004137,360–3.2%Recommendation 20The Committee proposes to leave ESR unchanged on the MBS.Rationale 20The Committee discussed the ESR literature review and noted its findings and limitations. The Committee noted that patients may require ESR testing to be eligible to access biological disease modifying anti-rheumatic drugs (bDMARDs) through the PBS. Although CRP testing can also be used for most patients, ESR still plays a role in determining which patients should initiate and/or continue bDMARD therapy.The Committee noted the following issues with ESR:ESR is very likely to have inferior performance to that of CRP for detection of inflammation.Biological variance between individuals is the reason that occasional samples are discordant in favour of ESR over CRP, and not reflective of a higher assay performance.Every time inflammatory biomarkers are evaluated head-to-head (i.e. each time a new marker becomes available, such as CD64, sCD14, PCT and SOFA), CRP outperforms ESR. Unfortunately historical indications (e.g. osteomyelitis, Hodgkin's disease) are not being revisited in this way, therefore there is an absence of evidence.On the other hand, for Hodgkin’s disease, for example, the European Organisation for Research and Treatment of Cancer (EORTC), National Cancer Institute of Canada (NCIC), and German Study Hodgkin Lymphoma Study Group (GSHG) use ESR (50?mm/hour if no B symptoms, 30?mm/hour with B symptoms), but other scoring systems such as the Hasencleaver use WBC instead. Some might consider that this suggests a WBC might be of comparable performance.In regard to sepsis and infection, these are all disappointing in studies with wider recruitment. Respiratory rate is a very good biomarker for sepsis, and much under-used.There is low clinical utility for the ESR item and the test is variable. ESR is considered to have a limited clinical role; however, international clinical guidelines still mention the use of ESR. It would be challenging to remove this test from the MBS without significant clinical ‘push back’.Recommendations to the Medical Services Advisory CommitteeThe Committee has also developed provisional recommendations for the consideration of other committees. The item-level recommendations can found below.Neuromyelitis optica (NMO) antibody testingRecommendation 21Create a new item for NMO-antibody testing with the following item descriptor wording:To investigate the presence of neuromyelitis optica by the detection of aquaporin 4 antibodies in serum and/or cerebrospinal fluid (CSF).Rationale 21The Committee recognises that the current MBS does not reflect current clinical practice and proposes that a new item be created for this test to be remunerated within the MBS.An NMO test is a test has been in clinical use for 10 years and is used to diagnose a treatable disease known as neuromyelitis optica. This disease is similar to multiple sclerosis and presents with optic neuritis and spinal cord inflammation that can lead to paraplegia and blindness.The disease can be diagnosed by other methods; however, this test provides a rapid diagnosis in young people. This test is important as it helps with diagnosis of neuromyelitis optica and it leads to specific treatment early in the course of the disease that can have a significant impact on patient outcomes.Use of this test is supported by the International consensus diagnostic criteria for neuromyelitis optica spectrum disorder.PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5XaW5nZXJjaHVrPC9BdXRob3I+PFllYXI+MjAxNTwvWWVh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==
ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5XaW5nZXJjaHVrPC9BdXRob3I+PFllYXI+MjAxNTwvWWVh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==
ADDIN EN.CITE.DATA [7] It is also supported by the European Federation of Neurological Societies guidelines on diagnosis and management of neuromyelitis optica.PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5TZWxsbmVyPC9BdXRob3I+PFllYXI+MjAxMDwvWWVhcj48
UmVjTnVtPjM8L1JlY051bT48RGlzcGxheVRleHQ+IFs4XTwvRGlzcGxheVRleHQ+PHJlY29yZD48
cmVjLW51bWJlcj4zPC9yZWMtbnVtYmVyPjxmb3JlaWduLWtleXM+PGtleSBhcHA9IkVOIiBkYi1p
ZD0iMDV0cnh3ZDlweGFmOW9lZXpkNnhydGUwcGZ0YXY1YWRlMHd3IiB0aW1lc3RhbXA9IjE0OTMy
NTcxOTAiPjM8L2tleT48L2ZvcmVpZ24ta2V5cz48cmVmLXR5cGUgbmFtZT0iSm91cm5hbCBBcnRp
Y2xlIj4xNzwvcmVmLXR5cGU+PGNvbnRyaWJ1dG9ycz48YXV0aG9ycz48YXV0aG9yPlNlbGxuZXIs
IEouPC9hdXRob3I+PGF1dGhvcj5Cb2dnaWxkLCBNLjwvYXV0aG9yPjxhdXRob3I+Q2xhbmV0LCBN
LjwvYXV0aG9yPjxhdXRob3I+SGludHplbiwgUi4gUS48L2F1dGhvcj48YXV0aG9yPklsbGVzLCBa
LjwvYXV0aG9yPjxhdXRob3I+TW9udGFsYmFuLCBYLjwvYXV0aG9yPjxhdXRob3I+RHUgUGFzcXVp
ZXIsIFIuIEEuPC9hdXRob3I+PGF1dGhvcj5Qb2xtYW4sIEMuIEguPC9hdXRob3I+PGF1dGhvcj5T
b3JlbnNlbiwgUC4gUy48L2F1dGhvcj48YXV0aG9yPkhlbW1lciwgQi48L2F1dGhvcj48L2F1dGhv
cnM+PC9jb250cmlidXRvcnM+PGF1dGgtYWRkcmVzcz5EZXBhcnRtZW50IG9mIE5ldXJvbG9neSwg
S2xpbmlrdW0gcmVjaHRzIGRlciBJc2FyLCBUZWNobmlzY2hlIFVuaXZlcnNpdGF0IE11bmNoZW4s
IEdlcm1hbnkuIHNlbGxuZXJAbHJ6LnR1bS5kZTwvYXV0aC1hZGRyZXNzPjx0aXRsZXM+PHRpdGxl
PkVGTlMgZ3VpZGVsaW5lcyBvbiBkaWFnbm9zaXMgYW5kIG1hbmFnZW1lbnQgb2YgbmV1cm9teWVs
aXRpcyBvcHRpY2E8L3RpdGxlPjxzZWNvbmRhcnktdGl0bGU+RXVyb3BlYW4gSm91cm5hbCBvZiBO
ZXVyb2xvZ3k8L3NlY29uZGFyeS10aXRsZT48YWx0LXRpdGxlPkV1cm9wZWFuIGpvdXJuYWwgb2Yg
bmV1cm9sb2d5PC9hbHQtdGl0bGU+PC90aXRsZXM+PHBlcmlvZGljYWw+PGZ1bGwtdGl0bGU+RXVy
IEogTmV1cm9sPC9mdWxsLXRpdGxlPjxhYmJyLTE+RXVyb3BlYW4gam91cm5hbCBvZiBuZXVyb2xv
Z3k8L2FiYnItMT48L3BlcmlvZGljYWw+PGFsdC1wZXJpb2RpY2FsPjxmdWxsLXRpdGxlPkV1ciBK
IE5ldXJvbDwvZnVsbC10aXRsZT48YWJici0xPkV1cm9wZWFuIGpvdXJuYWwgb2YgbmV1cm9sb2d5
PC9hYmJyLTE+PC9hbHQtcGVyaW9kaWNhbD48cGFnZXM+MTAxOS0zMjwvcGFnZXM+PHZvbHVtZT4x
Nzwvdm9sdW1lPjxudW1iZXI+ODwvbnVtYmVyPjxlZGl0aW9uPjIwMTAvMDYvMTA8L2VkaXRpb24+
PGtleXdvcmRzPjxrZXl3b3JkPkVsZWN0cm9kaWFnbm9zaXM8L2tleXdvcmQ+PGtleXdvcmQ+SHVt
YW5zPC9rZXl3b3JkPjxrZXl3b3JkPk1hZ25ldGljIFJlc29uYW5jZSBJbWFnaW5nPC9rZXl3b3Jk
PjxrZXl3b3JkPk1ldGh5bHByZWRuaXNvbG9uZS90aGVyYXBldXRpYyB1c2U8L2tleXdvcmQ+PGtl
eXdvcmQ+TmV1cm9teWVsaXRpcyBPcHRpY2EvKmRpYWdub3Npcy8qdGhlcmFweTwva2V5d29yZD48
a2V5d29yZD5OZXVyb3Byb3RlY3RpdmUgQWdlbnRzL3RoZXJhcGV1dGljIHVzZTwva2V5d29yZD48
a2V5d29yZD5QbGFzbWEgRXhjaGFuZ2U8L2tleXdvcmQ+PC9rZXl3b3Jkcz48ZGF0ZXM+PHllYXI+
MjAxMDwveWVhcj48cHViLWRhdGVzPjxkYXRlPkF1ZzwvZGF0ZT48L3B1Yi1kYXRlcz48L2RhdGVz
Pjxpc2JuPjE0NjgtMTMzMSAoRWxlY3Ryb25pYykmI3hEOzEzNTEtNTEwMSAoTGlua2luZyk8L2lz
Ym4+PGFjY2Vzc2lvbi1udW0+MjA1Mjg5MTM8L2FjY2Vzc2lvbi1udW0+PHdvcmstdHlwZT5SZXNl
YXJjaCBTdXBwb3J0LCBOb24tVS5TLiBHb3YmYXBvczt0JiN4RDtSZXZpZXc8L3dvcmstdHlwZT48
dXJscz48cmVsYXRlZC11cmxzPjx1cmw+aHR0cHM6Ly93d3cubmNiaS5ubG0ubmloLmdvdi9wdWJt
ZWQvMjA1Mjg5MTM8L3VybD48L3JlbGF0ZWQtdXJscz48L3VybHM+PGVsZWN0cm9uaWMtcmVzb3Vy
Y2UtbnVtPjEwLjExMTEvai4xNDY4LTEzMzEuMjAxMC4wMzA2Ni54PC9lbGVjdHJvbmljLXJlc291
cmNlLW51bT48bGFuZ3VhZ2U+ZW5nPC9sYW5ndWFnZT48YWNjZXNzLWRhdGU+NCBPY3RvYmVyIDIw
MTc8L2FjY2Vzcy1kYXRlPjwvcmVjb3JkPjwvQ2l0ZT48L0VuZE5vdGU+AG==
ADDIN EN.CITE PEVuZE5vdGU+PENpdGU+PEF1dGhvcj5TZWxsbmVyPC9BdXRob3I+PFllYXI+MjAxMDwvWWVhcj48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ADDIN EN.CITE.DATA [8] This test is mainly used by neurologists to diagnose this disease.The Committee recommends an education campaign on the utility and frequency of test. In most samples, testing will be for diagnosis only. Patients will often require repeat testing to see whether they have had a relapse. Significant changes in antibody levels will not occur more often than every 3 months. Over-testing for antibody levels does not add clinical value. The Committee estimates the utilisation of this test to be 5000 per year based on the prevalence of NMO in a study that was reported as 0.33 per 100,000. ADDIN EN.CITE <EndNote><Cite><Author>Bukhari</Author><Year>2015</Year><RecNum>4</RecNum><DisplayText> [9]</DisplayText><record><rec-number>4</rec-number><foreign-keys><key app="EN" db-id="05trxwd9pxaf9oeezd6xrte0pftav5ade0ww" timestamp="1493257428">4</key></foreign-keys><ref-type name="Web Page">12</ref-type><contributors><authors><author>Bukhari, W.</author><author>Broadley, S.</author></authors></contributors><titles><title>The prevalence of neuromyelitis optica in Australia and New Zealand and a blood test for its diagnosis</title></titles><number>4 October 2017</number><dates><year>2015</year></dates><publisher>MS Research Australia</publisher><urls><related-urls><url>; [9]Antibodies to citrullinated peptide antigens These antibodies are also referred to as cyclic citrullinated peptide antibodies (CCP).Recommendation 22Create a new item for cyclic citrullinated peptide antibodies with the following wording:Investigation for rheumatoid arthritis: citrullinated peptide antibodies.Add rule 25 to restrict this item to three tests within a 12-month period.Table SEQ Table \* ARABIC 37. Proposed new item descriptor for antibodies to citrullinated peptide antigensItemItem descriptorNew itemInvestigation for rheumatoid arthritis: citrullinated peptide antibodies, excludes item 71119. (Item is subject to rule 25)Rationale 22The Committee recognises that this test has been in clinical practice for about 15 years; however, this test has not been on the MBS. Currently there is no item specifically for this test and it is being billed under item 71119. This is a high-utility test that impacts greatly on treatment and disease classification. It is a robust test that produces quality results when there is an increase in antibodies. It is the standard of care in rheumatoid arthritis to have this test done and it has high clinical utility in the monitoring of drugs but not in monitoring of disease. The Committee recognises that the current schedule does not reflect current clinical practice and proposes that a new item be created for this test to be remunerated (at a higher rate than item 71119, which is currently being used to capture this test) within the MBS. The Committee estimates the utilisation to be approximately 150,000 services per annum. The Committee has proposed that this item also be limited to three tests in a 12-month period, as there is no clinical need to test more often than this. Other biomarkers are available that are superior for disease monitoring, such as CRP or swollen and/or tender joint count.References ADDIN EN.REFLIST [1] Elshaug, A G, A M Watt, L Mundy and C D Willis. Over 150 potentially low-value health care practices: an Australian study. Med J Aust 2012, vol. 197, no. 10, pp. 556-560.[2] Anderson, R P, M J Henry, R Taylor, E L Duncan, P Danoy, M J Costa, K Addison, J A Tye-Din, M A Kotowicz, R E Knight, W Pollock, G C Nicholson, B H Toh, M A Brown and J A Pasco. A novel serogenetic approach determines the community prevalence of celiac disease and informs improved diagnostic pathways. BMC Medicine 2013, vol. 11, no. 1, pp. 188.[3] Bibbins-Domingo, K, D C Grossman, S J Curry, M J Barry, K W Davidson, C A Doubeni, M Ebell, J W Epling, Jr., J Herzstein, A R Kemper, A H Krist, A E Kurth, C S Landefeld, C M Mangione, M G Phipps, M Silverstein, M A Simon and C W Tseng. Screening for Celiac Disease: US Preventive Services Task Force Recommendation Statement. Journal of the American Medical Association 2017, vol. 317, no. 12, pp. 1252-1257.[4] O’Sullivan, M, A McLean-Tooke and R Loh. Antinuclear antibody test. Australian Family Physician 2013, vol. 42, no. pp. 718-721.[5] Smolen, J S, R Landewé, J Bijlsma, G Burmester, K Chatzidionysiou, M Dougados, J Nam, S Ramiro, M Voshaar, R van Vollenhoven, D Aletaha, M Aringer, M Boers, C D Buckley, F Buttgereit, V Bykerk, M Cardiel, B Combe, M Cutolo, Y van Eijk-Hustings, P Emery, A Finckh, C Gabay, J Gomez-Reino, L Gossec, J-E Gottenberg, J M W Hazes, T Huizinga, M Jani, D Karateev, M Kouloumas, T Kvien, Z Li, X Mariette, I McInnes, E Mysler, P Nash, K Pavelka, G Poór, C Richez, P van Riel, A Rubbert-Roth, K Saag, J da Silva, T Stamm, T Takeuchi, R Westhovens, M de Wit and D van der Heijde. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Annals of the Rheumatic Diseases 2017, vol. 76, no. 6, pp. 960-977.[6] Miyakis, S, M D Lockshin, T Atsumi, D W Branch, R L Brey, R Cervera, R H Derksen, D E G PG, T Koike, P L Meroni, G Reber, Y Shoenfeld, A Tincani, P G Vlachoyiannopoulos and S A Krilis. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006, vol. 4, no. 2, pp. 295-306.[7] Wingerchuk, D M, B Banwell, J L Bennett, P Cabre, W Carroll, T Chitnis, J de Seze, K Fujihara, B Greenberg, A Jacob, S Jarius, M Lana-Peixoto, M Levy, J H Simon, S Tenembaum, A L Traboulsee, P Waters, K E Wellik and B G Weinshenker. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015, vol. 85, no. 2, pp. 177-189.[8] Sellner, J, M Boggild, M Clanet, R Q Hintzen, Z Illes, X Montalban, R A Du Pasquier, C H Polman, P S Sorensen and B Hemmer. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol 2010, vol. 17, no. 8, pp. 1019-1032. [9] Bukhari, W and S Broadley. The prevalence of neuromyelitis optica in Australia and New Zealand and a blood test for its diagnosis [online]. MS Research Australia, 2015 [accessed 4 October 2017]. Retrieved: annual growth rate, or the average annual growth rate over a specified time period.ChangeDescribes when the item and/or its services will be affected by the recommendations. This could result from a range of recommendations, such as: (i) specific recommendations that affect the services provided by changing item descriptors or explanatory notes, (ii) the consolidation of item numbers, and (iii) splitting item numbers (e.g. splitting the current services provided across two or more items). CRPC-reactive proteinDeleteDescribes when an item is recommended for removal from the MBS and its services will no longer be provided under the MBS.FYFinancial yearGPGeneral practitionerHigh-value careServices of proven efficacy reflecting current best medical practice, or for which the potential benefit to consumers exceeds the risk and costs.IgImmunoglobulinInappropriate use/misuseUse of MBS services for purposes other than those intended. This includes a range of behaviours, from failing to adhere to particular item descriptors or rules through to deliberate fraud.Low-value careUse of an intervention that evidence suggests confers little benefit or no benefit to patients; or when the risk of harm from the intervention exceeds the likely benefit; or, more broadly, when the added costs of the intervention do not provide proportional added benefits.MBSMedicare Benefits Schedule MBS itemAn administrative object listed in the MBS and used for the purposes of claiming and paying Medicare benefits, consisting of an item number, service descriptor and supporting information, schedule fee and Medicare benefits.MBS serviceThe actual medical consultation, procedure or test to which the relevant MBS item refers.MSACMedical Services Advisory CommitteeMultiple services rules A set of rules governing the amount of Medicare benefit payable for multiple services provided to a patient at the same attendance (same day). New serviceDescribes when a new service has been recommended, with a new item number. In most circumstances these will need to go through MSAC. It is worth noting that implementation of the recommendation may result in more or fewer item numbers than specifically stated. No change or unchangedDescribes when the services provided under these items will not be changed or affected by the recommendations. This does not rule out small changes in item descriptors (e.g. references to other items, which may have changed as a result of the MBS Review or prior reviews).Obsolete services/items Services that should no longer be performed, as they do not represent current clinical best practice and have been superseded by superior tests or procedures.PEIPatient episode initiationPBSPharmaceutical Benefits SchemePCCPathology Clinical Committee PSACPathology Services Advisory CommitteeRARheumatoid arthritisRACGPRoyal Australian College of General PractitionersRule 25For any particular patient, this item is applicable not more than once in a 12-month periodThe Taskforce MBS Review Taskforce Appendix A – Immunology-related pathology test items – recommendations listTable A1. MBS items considered by the committeeItemCurrent descriptor RecommendationSection reference 71163Detection of one of the following antibodies (of 1 or more class or isotype) in the assessment or diagnosis of coeliac disease or other gluten hypersensitivity syndromes and including a service described in item 71066 (if performed): a) Antibodies to gliadin; or b) Antibodies to endomysium; or c) Antibodies to tissue transglutaminase; - 1 testChange4.1.171164Two or more tests described in 71163 and including a service described in 71066 (if performed)No change4.1.171151Tissue typing for HLA-DR, HLA-DP and HLA-DQ Class II antigens (including any separation of leucocytes) - phenotyping or genotyping of 2 or more antigensChange4.2.171079Detection of specific immunoglobulin E (IgE) antibodies to single or multiple potential allergens, 1 test (Item is subject to rule 25)Change4.3.171097Antinuclear antibodies - detection in serum or other body fluids, including quantitation if requiredChange4.4.171099Double-stranded DNA antibodies - quantitation by 1 or more methods other than the Crithidia methodChange4.5.171101Antibodies to 1 or more extractable nuclear antigens - detection in serum or other body fluidsChange4.6.171103Characterisation of an antibody detected in a service described in item 71101 (including that service)Change4.6.171083Quantitation of complement components C3 and C4 or properdin factor B – 1 testChange4.7.1710852 tests described in item 71083Change4.7.1710873 or more tests described in item 71083Delete4.7.171089Quantitation of complement components or breakdown products of complement proteins not elsewhere described in an item in this Schedule - 1 test (Item is subject to rule 6)Change4.7.1710912 tests described in item 71089 (Item is subject to rule 6)Change4.7.1710933 or more tests described in item 71089 (Item is subject to rule 6)Change4.7.171119Antibodies to tissue antigens not elsewhere specified in this Table - detection, including quantitation if required, of 1 antibodyNo change4.8.171121Detection of 2 antibodies specified in item 71119No change4.8.171123Detection of 3 antibodies specified in item 71119No change4.8.171125Detection of 4 or more antibodies specified in item 71119Change4.8.171165Antibodies to tissue antigens (acetylcholine receptor, adrenal cortex, heart, histone, insulin, insulin receptor, intrinsic factor, islet cell, lymphocyte, neuron, ovary, parathyroid, platelet, salivary gland, skeletal muscle, skin basement membrane and intercellular substance, thyroglobulin, thyroid microsome or thyroid stimulating hormone receptor) - detection, including quantitation if required, of 1 antibody (Item is subject to rule 6)Change4.9.171075Quantitation of immunoglobulin E (total), (IgE) 1 test. (Item is subject to rule 25)Change4.10.171077Quantitation of immunoglobulin E (total) (IgE) in the follow up of a patient with proven immunoglobulin-E-secreting myeloma, proven congenital immunodeficiency or proven allergic bronchopulmonary aspergillosis, 1 test. (Item is subject to rule 25)Delete4.10.171066Quantitation of total immunoglobulin a by any method in serum, urine or other body fluid – 1 testChange4.11.171072Quantitation of total immunoglobulin m by any method in serum, urine or other body fluid - 1 testChange4.12.171074Quantitation of total immunoglobulin d by any method in serum, urine or other body fluid - 1 testChange4.13.171064Detection and quantitation of cryoglobulins or cryofibrinogen - 1 or more testsChange4.14.171106Rheumatoid factor - detection by any technique in serum or other body fluids, including quantitation if requiredChange4.15.171180Antibody to cardiolipin or beta-2 glycoprotein I detection, including quantitation if required; one antibody specificity (IgM or IgG)Change4.16.171183Detection of two antibodies described in item 71180No change4.16.171186Detection of three or more antibodies described in item 71180No change4.16.171200Detection and quantitation, if present, of free kappa and lambda light chains in serum for the diagnosis or monitoring of amyloidosis, myeloma or plasma cell dyscrasias.Change4.17.171095Quantitation of serum or plasma eosinophil cationic protein, or both, to a maximum of 3 assays in 1 year, for monitoring the response to therapy in corticosteroid treated asthma, in a child aged less than 12 yearsDelete4.18.171096A test described in item 71095 if rendered by a receiving APP, (Item is subject to rule 18)Delete4.18.171137Quantitation of cell-mediated immunity by multiple antigen delayed type hypersensitivity intradermal skin testing using a minimum of 7 antigens, 1 of this item to a maximum of 2 in a 12 month periodDelete4.18.171203Determination of hlab5701 status by flow cytometry or cytotoxity assay prior to the initiation of abacavir therapy including item 73323 if performed.Delete4.18.171170Tests described in item 71165, other than that described in 71169, if rendered by a receiving APP – each test to a maximum of 3 tests. (Item is subject to rule 6 and 18.) No change4.19.171057Electrophoresis, quantitative and qualitative, of serum, urine or other body fluid all collected within a 28 day period, to demonstrate: (a) protein classes; or (b) presence and amount of paraprotein; including the preliminary quantitation of total protein, albumin and globulin - 1 specimen typeNo change4.19.171058Examination as described in item 71057 of 2 or more specimen typesNo change4.19.171059Immunofixation or immunoelectrophoresis or isoelectric focusing of:(a) urine for detection of bence jones proteins; or(b) serum, plasma or other body fluid; and characterisation of a paraprotein or cryoglobulin -examination of 1 specimen type (e.g. serum, urine or csf) No change4.19.171060Examination as described in item 71059 of 2 or more specimen typesNo change4.19.171062Electrophoresis and immunofixation or immunoelectrophoresis or isoelectric focussing of CSF for the detection of oligoclonal bands and including if required electrophoresis of the patient's serum for comparison purposes - 1 or more testsNo change4.19.171068Quantitation of total immunoglobulin g by any method in serum, urine or other body fluid - 1 testNo change4.19.1710692 tests described in items 71066, 71068, 71072 or 71074No change4.19.1710713 or more tests described in items 71066, 71068, 71072 or 71074No change4.19.171073Quantitation of all 4 immunoglobulin G subclassesNo change4.19.171076A test described in item 71073 if rendered by a receiving APP - 1 test(Item is subject to rule 18)No change4.19.171081Quantitation of total haemolytic complementNo change4.19.171090A test described in item 71089, if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP - 1 test(Item is subject to rule 6 and 18)No change4.19.171092Tests described in item 71089, other than that described in 71090, if rendered by a receiving APP - each test to a maximum of 2 tests(Item is subject to rule 6 and 18)No change4.19.171127Functional tests for lymphocytes - quantitation other than by microscopy of: (a) proliferation induced by 1 or more mitogens; or (b) proliferation induced by 1 or more antigens; or (c) estimation of 1 or more mixed lymphocyte reactions; including a test described in item 65066 or 65070 (if performed), 1 of this item to a maximum of 2 in a 12 month periodNo change4.19.1711292 tests described in item 71127No change4.19.1711313 or more tests described in item 71127No change4.19.171133Investigation of recurrent infection by qualitative assessment for the presence of defects in oxidative pathways in neutrophils by the nitroblue tetrazolium (nbt) reduction testNo change4.19.171134Investigation of recurrent infection by quantitative assessment of oxidative pathways by flow cytometric techniques, including a test described in 71133 (if performed)No change4.19.171135Quantitation of neutrophil function, comprising at least 2 of the following: (a) chemotaxis; (b) phagocytosis; (c) oxidative metabolism; (d) bactericidal activity; including any test described in items 65066, 65070, 71133 or 71134 (if performed), 1 of this item to a maximum of 2 in a 12 month periodNo change4.19.171139Characterisation of 3 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations, including a total lymphocyte count or total leucocyte count by any method, on 1 or more specimens of blood, CSF or serous fluidNo change4.19.171141Characterisation of 3 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations on 1 or more disaggregated tissue specimensNo change4.19.171143Characterisation of 6 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations for the diagnosis (but not monitoring) of an immunological or haematological malignancy, including a service described in 1 or both of items 71139 and 71141 (if performed), on a specimen of blood, CSF, serous fluid or disaggregated tissueNo change4.19.171145Characterisation of 6 or more leucocyte surface antigens by immunofluorescence or immunoenzyme techniques to assess lymphoid or myeloid cell populations for the diagnosis (but not monitoring) of an immunological or haematological malignancy, including a service described in 1 or more of items 71139, 71141 and 71143 (if performed), on 2 or more specimens of disaggregated tissues or 1 specimen of disaggregated tissue and 1 or more specimens of blood, CSF or serous fluidNo change4.19.171146Enumeration of cd34+ cells, only for the purposes of autologous or directed allogeneic haemopoietic stem cell transplantation, including a total white cell count on the pherisis collectionNo change4.19.171147HLA-B27 typing (Item is subject to rule 27)No change4.19.171148A test described in item 71147 if rendered by a receiving APP. (Item is subject to rule 18 and 27)No change4.19.171149Complete tissue typing for 4 HLA-A and HLA-B Class I antigens (including any separation of leucocytes), including (if performed) a service described in item 71147No change4.19.171153Investigations in the assessment or diagnosis of systemic inflammatory disease or vasculitis - antineutrophil cytoplasmic antibody immunofluorescence (anca test), antineutrophil proteinase 3 antibody (pr-3 anca test), antimyeloperoxidase antibody (mpo anca test) or antiglomerular basement membrane antibody (gbm test) - detection of 1 antibody (item is subject to rule 6 and 23)No change4.19.171154A test described in item 71153, if rendered by a receiving APP, where no tests in the item have been rendered by the referring APP - 1 test.(Item is subject to rule 6, 18 and 23)No change4.19.171155Detection of 2 antibodies described in item 71153No change4.19.171156Tests described in item 71153, other than that described in 71154, if rendered by a receiving APP each test to a maximum of 3 tests(Item is subject to rule 6, 18 and 23)No change4.19.171157Detection of 3 antibodies described in item 71153 (item is subject to rule 6 and 23)No change4.19.171159Detection of 4 or more antibodies described in item 71153 (Item is subject to rule 6 and 23)No change4.19.171189Detection of specific IgG antibodies to 1 or more respiratory disease allergens not elsewhere specified.No change4.19.1711922 items described in item 71189.No change4.19.1711953 or more items described in item 71189.No change4.19.171198Estimation of serum tryptase for the evaluation of unexplained acute hypotension or suspected anaphylactic event, assessment of risk in stinging insect anaphylaxis, exclusion of mastocytosis, monitoring of known mastocytosis.No change4.19.165060Haemoglobin, erythrocyte sedimentation rate, blood viscosity -1 or more testsNo change5.1.1Appendix B – Summary for consumersThis summary describes the medical service, the recommendations of the clinical experts and why the recommendation(s) has been made.Recommendation 1: Coeliac disease testsItemsWhat it doesCommittee recommendationWhat would be differentWhy71163, 71164These tests detect one (71163) or more (71164) immune-responses to gluten. They are used to diagnose coeliac disease or gluten-hypersensitivity syndromes.Advise health professionals on the appropriate use of these tests.Limit testing to four times a year per patientThe description of the test would be changed to reflect the Committee’s recommendations, so that only at-risk people qualify for testingMany more people are being tested than end up having the condition, possibly because increased awareness campaigns about gluten intolerance have overstated how common coeliac disease is. Recommendation 2: Genotyping for coeliac disease risk for DQ2 and DQ8ItemWhat it doesCommittee recommendationWhat would be differentWhy71151 and new itemThis item provides rebates for ‘tissue typing’ tests, which are needed when transplanting organs and tissues.This item can currently be used to test for the ‘DQ2’ and ‘DQ8’ genes, which can indicate whether a person has coeliac disease.Change the description of the existing item to prevent it from being used to check for coeliac disease.Create a new item to use specifically for checking for coeliac disease and limit it to twice a year per patient.Only the new test would be used to check for the possibility coeliac diseaseIt is likely that requests for testing tissue types in possible coeliac disease are being included under existing item 71151, which includes other tests not related to coeliac disease.Recommendation 3: Specific immunoglobulin E antibodiesItemWhat it doesCommittee recommendationWhat would be differentWhy71079This test is used to detect allergic responses to specific allergens, by detecting and measuring immunoglobulin E (a type of antibody associated with allergic reactions).Create a new item for the newer, more accurate (but more expensive) tests that have been developed for measuring IgE. Keep only the older, more established tests in the current item. Limit testing with the new test to four times a year per patient.Overuse of the newer techniques would be reduced, and a separate test would enable monitoring of how many people require the newer techniques and who requests them.To enable more accurate diagnosis and greater monitoring.Recommendation 4: Antinuclear antibodies testsItemWhat it doesCommittee recommendationWhat would be differentWhy71097An antinuclear antibody is an antibody that targets the “normal” proteins where the DNA is stored inside cells.The presence of large amount of antinuclear antibodies can indicate a person has an autoimmune disease.This test is used to measure the amount of antinuclear antibodies a person has.Educate health professionals about correct use of this test.Health professionals would better understand the intended use of repeat testing for this item, reducing incorrect use of the testIn some patients, this test is being ordered too frequently without any clinical benefit to the patient.Recommendation 5: Double-stranded DNA antibodiesItemWhat it doesCommittee recommendationWhat would be differentWhy71099A double stranded DNA antibody is an antibody that targets DNA within a person’s own body.The presence of large amount of this antibody can indicate a person has an autoimmune disease.This test determines if a person has any double stranded DNA antibodies.Change the description so that the ‘Crithidia method’ is not excludedThe test would no longer exclude this method of testing for an immune response against the body’s own DNAThe Crithidia method is considered to be a valid test and there is no reason to exclude itRecommendation 6: Antibodies to extractable nuclear antigensItemsWhat it doesCommittee recommendationWhat would be differentWhy71101, 71103Extracts (71101) and identifies (71103) inappropriate immune responses to various proteins from the cell nucleus (central portion of the cell containing DNA/genes)Change item 71101 to ensure that the test is performed using serum.Monitor items 71101 and 71103.Audit laboratories where the ratio of item 71103: 71101 is more than one third.Testing would only be possible four times a year for individual patientsTest 71101 may be being repeated unnecessarily for monitoring (it should only be repeated if the patient’s condition changes)Recommendation 7: Quantitation of complement componentsItemWhat it doesCommittee recommendationWhat would be differentWhy71083, 71085, 71087, 71089, 71091, 71093Tests for chemicals produced by the body in an immune response, which complement the response by immune cellsDelete item 71087 and update the descriptions for the other items to reflect advances in testing and remove outdated informationItem 71087 would no longer be available, while the descriptions for the remaining items would be brought into line with advances in testingItem 71087 is now outdated. Knowledge and use of the more advanced testing has increased, so the available tests need to reflect thisRecommendation 8: Antibodies to tissue antigensItemWhat it doesCommittee recommendationWhat would be differentWhy71119, 71121, 71123, 71125Identifies inappropriate immune responses to specific body tissues not included in the next RecommendationCreate a new item to capture how many people have 5 or more such immune responsesWe could know how many patients need 4 tests and how many needed 5 or more (we can’t do this currently)Some patients need a test for 4 specific immune responses, others for 5 or more to identify the cause of their disease Patients with one abnormal immune response have a tendency to produce more than one immune responseRecommendation 9: Antibodies to tissue antigensItemWhat it doesCommittee recommendationWhat would be differentWhy71165Identifies inappropriate immune responses to specific body tissuesRemove the references to thyroid gland and salivary glandThe item description would not refer to testing for immune responses to these two glandsThe salivary gland test is no longer considered useful, and a new thyroid test is proposed in the pathology section of the MBSRecommendation 10: Quantitation of Immunoglobulin EItemWhat it doesCommittee recommendationWhat would be differentWhy71075, 71077Measures the extent of an immune response handled by ‘IgE’ (one of the body’s main immune molecules), either at an initial consultation (item 71077) or when following up certain conditions (71077)Merge these two items into one and limit testing to four times a year per patientItem 71077 would be merged into item 71075, with the lower cost of 71077 applied to 71075, then item 71077 would be deletedItem 71077 is under-used because of difficulty with the description and higher cost. The changes will simplify the MBS.Recommendation 11: Quantitation of total Immunoglobulin AItemWhat it doesCommittee recommendationWhat would be differentWhy71072Measures the extent of an immune response handled by ‘IgM’ (one of the body’s main immune molecules)Remove the words ‘urine or other body fluid’ from the descriptionThe test would refer only to blood serum, not to urine or other body fluidsThis test should not be performed using urine or other body fluids as it is of no medical valueRecommendation 12: Quantitation of total Immunoglobulin MItemWhat it doesCommittee recommendationWhat would be differentWhy71072Measures the extent of an immune response handled by ‘IgM’ (one of the body’s main immune molecules)Remove the words ‘urine or other body fluid’ from the descriptionThe test would refer only to blood serum, not to urine or other body fluidsThis test should not be performed using urine or other body fluids as it is of no medical value71072Measures the extent of an immune response handled by ‘IgM’ (one of the body’s main immune molecules)Remove the words ‘urine or other body fluid’ from the descriptionThe test would refer only to blood serum, not to urine or other body fluidsThis test should not be performed using urine or other body fluids as it is of no medical valueRecommendation 13: Quantitation of total Immunoglobulin D ItemWhat it doesCommittee recommendationWhat would be differentWhy71074Measures the extent of an immune response handled by ‘IgD’ (one of the body’s main immune molecules)Remove the words ‘urine or other body fluid’ from the descriptionThe test would refer only to blood serum, not to urine or other body fluidsThis test should not be performed using urine or other body fluids as it is of no medical valueRecommendation 14: Cryoglobulins or cryofibrinogenItemWhat it doesCommittee recommendationWhat would be differentWhy71064Checks for abnormal forms of these molecules in the blood which are sensitive to coldIncrease the Schedule fee for this itemThe new cost would cover the test’s actual cost including specialised collection and transportThe current Schedule fee does not reflect the associated costs because cryoglobulins are very expensive to collect and transportRecommendation 15: Rheumatoid factorItemWhat it doesCommittee recommendationWhat would be differentWhy71106Detects a specific inappropriate immune response against IgG (one of the body’s main immune molecules) seen in rheumatoid arthritisLimit testing to four times a year per patient, and educate rheumatologists on appropriate useThe current overuse of the test would be reducedTesting more than 4 times a year is inappropriate because it is of no medical value. Education needs to address testing by rheumatologistsRecommendation 16: Antibody to cardiolipinItemWhat it doesCommittee recommendationWhat would be differentWhy71180, 71183, 71186Detects an inappropriate immune response against cardiolipin, seen in a range of diseasesChange the description of item 71180 to include immunoglobulin A (IgA [another of the body’s main immune molecules]). Limit testing to four times a year per patientIgA testing would be included with IgG and IgM testing.Overuse of the test would be prevented.IgA testing is also of value together with IgG and IgM testing r for detecting this immune response.Recommendation 17: Free kappa and lambda light chainsItemWhat it doesCommittee recommendationWhat would be differentWhy71200Measures the amounts of these components, which are elevated in certain types of blood cancers (myeloma)Change the description to prevent the test being used to diagnose/monitor lymphomaRequesters (mainly haematologists) would not be able to use to this test for diagnosing/monitoring lymphomaUse of this test is increasing more than it should. Others test should be used to diagnose/monitor lymphomaRecommendation 21: NMO testingItemWhat it doesCommittee recommendationWhat would be differentWhyNew itemProvides rapid diagnosis of this newly-described condition to 3 times a year per patientCreate a new item for this testThe new test would provide access that wasn’t available beforeUse of this test is supported by expert international guidelines and consensusRecommendation 22: Antibodies to citrullinated peptide antigensItemWhat it doesCommittee recommendationWhat would be differentWhyNew itemTests for this inappropriate immune response seen in rheumatoid arthritisCreate a new item for this test and limit it to 4 times a year per patientA new item would be available to test specifically for this inappropriate immune response, and overuse preventedRequesters have been using this test for about 15 years but it has not been on the MBS. It is included with other tests in item 71119 so requesters have been using that instead ................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related download
- defining cancer risk and assessing diagnostic usefulness
- medicare benefits schedule review taskforce report from
- novel antibodies
- the use of gmdn codes for ivd medical devices in australia
- sipuleucel t drug monograph pharmacy benefit management
- procedure home tan tock seng hospital
- proposed changes to the national blood authority
Related searches
- medicare fee schedule for vaccines
- medicare fee schedule for immunizations
- medicare fee schedule lookup
- 2013 medicare fee schedule lookup
- 2013 medicare fee schedule download
- 2017 medicare fee schedule lookup
- asc medicare fee schedule 2021
- medicare fee schedule for 2021
- 2008 medicare fee schedule download
- 2012 medicare fee schedule lookup
- 2012 medicare fee schedule pdf
- 2014 medicare fee schedule download